tổng hợp và thử hoạt tính sinh học của một số dẫn chất ức chế hdac-...

177
BỘ GIÁO DỤC VÀ ĐÀO TẠO BỘ Y TẾ TRƯỜNG ĐẠI HỌC DƯỢC HÀ NỘI ĐÀO THỊ KIM OANH TỔNG HỢP VÀ THỬ HOẠT TÍNH SINH HỌC CỦA MỘT SỐ DẪN CHẤT ACID HYDROXAMIC HƯỚNG ỨC CHẾ ENZYM HISTON DEACETYLASE LUẬN ÁN TIẾN SĨ DƯỢC HỌC HÀ NỘI 2013

Upload: forumchemitry

Post on 14-Sep-2015

70 views

Category:

Documents


6 download

DESCRIPTION

Tổng Hợp Và Thử Hoạt Tính Sinh Học Của Một số dẫn chất ức chế HDAC- 3-hydroxy

TRANSCRIPT

  • B GIO DC V O TO B Y T

    TRNG I HC DC H NI

    O TH KIM OANH

    TNG HP V TH HOT TNH

    SINH HC CA MT S DN CHT

    ACID HYDROXAMIC HNG C CH

    ENZYM HISTON DEACETYLASE

    LUN N TIN S DC HC

    H NI 2013

  • B GIO DC V O TO B Y T

    TRNG I HC DC H NI

    O TH KIM OANH

    TNG HP V TH HOT TNH

    SINH HC CA MT S DN CHT

    ACID HYDROXAMIC HNG C CH

    ENZYM HISTON DEACETYLASE

    LUN N TIN S DC HC

    CHUYN NGNH HA DC

    M S: 62.72.04.03

    Ngi hng dn khoa hc: PGS.TS. Nguyn Hi Nam

    GS.TS. Sang-Bae Han

    H NI 2013

  • i

    LI CAM OAN

    Ti xin cam oan y l cng trnh nghin cu ca ring ti.

    Cc s liu, kt qu c trnh by trong lun n l trung thc, khch quan v

    cha tng c ai cng b trong bt k cng trnh no khc.

    Tc gi lun n

    o Th Kim Oanh

  • ii

    LI CM N

    Trong qu trnh nghin cu v hon thnh lun n, ti nhn c s gip

    qu bu ca cc thy c gio, cc nh khoa hc thuc nhiu lnh vc cng ng

    nghip, gia nh v bn b.

    u tin, ti xin c gi li cm n chn thnh v s bit n su sc ti

    PGS.TS. Nguyn Hi Nam, GS.TS. Sang-Bae Han, nhng ngi thy tn tnh

    hng dn v to mi iu kin gip ti trong sut qu trnh nghin cu c Vit

    Nam v Hn Quc.

    Ti xin chn thnh cm n cc ng nghip ti b mn Ha dc ng h,

    ng vin ti trong qu trnh nghin cu.

    Trong thi gian thc hin lun n, ti nhn c s phi hp, gip ca

    cc c nhn, n v trong v ngoi trng. Ti xin chn thnh cm n cc anh ch

    Phng th nghim trung tm Trng i hc Dc H Ni, Khoa ha hc Trng

    i hc Khoa hc t nhin i hc Quc gia H Ni, Phng cng hng t - Vin

    ha hc Vin Khoa hc v Cng ngh Vit Nam, Phng khi ph - Vin ha hc cc

    hp cht thin nhin - Vin Khoa hc v Cng ngh Vit Nam, cc bn nghin cu

    sinh ca b mn Dc l, Khoa Dc, Trng i hc Quc gia Chungbuk

    (Cheongju, Hn Quc).

    Ti xin chn thnh cm n ng y, Ban gim hiu, Phng o to sau i hc,

    cc b mn v phng ban chc nng Trng i hc Dc H Ni to iu kin

    thun li cho ti trong thi gian hc tp v hon thnh lun n ny.

    Cui cng, xin gi li cm n su sc ti chng v hai con trai, ngi thn, bn

    b lun l nhng ngi ng vin, l ng lc gip ti phn u hon thnh lun

    n.

    Mt ln na, xin chn thnh cm n tt c nhng s gip qu bu m mi

    ngi dnh cho ti.

    o Th Kim Oanh

  • iii

    MC LC

    Trang

    Danh mc cc k hiu, ch vit tt

    Danh mc cc bng

    Danh mc cc hnh v, s

    T VN 1

    CHNG 1. TNG QUAN 2

    1.1. Histon deacetylase 2

    1.1.1. Histon acetyltransferase 4

    1.1.2. Histon deacetylase 4

    1.1.2.1. Phn loi 5

    1.1.2.2. Cu trc ca HDAC v c ch phn ng deacetyl ha 7

    1.1.3. Mi lin quan gia ung th v s bt thng hot ng ca HAT

    hoc HDAC

    10

    1.2. Cc cht c ch HDAC 11

    1.2.1. Phn loi 11

    1.2.2. C ch tc dng ca cc cht c ch HDAC 14

    1.2.3. Cu trc ca cc cht c ch HDAC 17

    1.3. Tnh hnh nghin cu trn th gii v cc cht c ch HDAC 18

    1.3.1. Cc peptid vng 19

    1.3.2. Dn cht benzamid 20

    1.3.3. Cc acid bo mch ngn 21

    1.3.4. Cc dn cht ceton 22

    1.3.5. Cc hydroxamat v dn cht 22

    1.3.5.1. Thay i cu ni 24

    1.3.5.2. Thay i nhm kha hot ng 29

    1.3.5.3. Thay i nhm chc hydroxamic 34

    1.4. Cc phng php to lin kt amid v tng hp acid hydroxamic 39

    1.4.1. Cc phng php to lin kt amid 39

    1.4.1.1. Acyl halid 40

    1.4.1.2. Acyl azid 41

  • iv

    1.4.1.3. Acylimidazol 41

    1.4.1.4. Anhydrid 42

    1.4.1.5. Ester 43

    1.4.2. Cc phng php tng hp acid hydroxamic 45

    1.4.2.1. Tng hp acid hydroxamic t ester 45

    1.4.2.2. Tng hp acid hydroxamic t acid carboxylic 45

    CHNG 2. NGUYN LIU, THIT B, NI DUNG V PHNG

    PHP NGHIN CU

    47

    2.1. Nguyn liu 47

    2.2. Thit b 48

    2.3. Ni dung v phng php nghin cu 49

    2.3.1. Ni dung nghin cu 49

    2.3.2. Phng php nghin cu 49

    2.3.2.1. Phng php tng hp 49

    2.3.2.2. Phng php kim tra tinh khit 51

    2.3.2.3 Phng php phn tch cu trc 52

    2.3.2.4. Phng php th hot tnh sinh hc 53

    2.3.2.5. Docking 56

    CHNG 3. KT QU NGHIN CU 57

    3.1. Tng hp ha hc v phn tch d liu ph 57

    3.1.1. Cc dn cht N1-(benzo[d]thiazol-2-yl)-N4-hydroxysuccinamid v

    N1-(benzo[d]thiazol-2-yl)-N5-hydroxyglutaramid

    57

    3.1.1.1. Kt qu tng hp 57

    3.1.1.2. Kt qu phn tch ph ca cc dn cht 3a-f v 5a-f 63

    3.1.2. Cc dn cht N1-(benzo[d]thiazol-2-yl)-N6-hydroxyadipamid v

    N1-(benzo[d]thiazol-2-yl)-N8-hydroxyoctandiamid

    66

    3.1.2.1. Kt qu tng hp 66

    3.1.2.2. Kt qu phn tch ph ca cc dn cht 7a-f v 9a-h 73

    3.1.3. Tng hp cht N1-(thiazol-2-yl)-N8-hydroxyoctandiamid (23) 76

    3.1.4. Cc dn cht N1-(benzo[d]thiazol-2-yl)-N4-(3-(hydroxyamino)-3-

    oxopropyl)succinamid v N1-(benzo[d]thiazol-2-yl)-N5-(2-(hydroxy

    amino)-2-oxoethyl)glutaramid

    77

  • v

    3.1.4.1. Kt qu tng hp 77

    3.1.4.2. Kt qu phn tch ph ca cc dn cht 11a-d v 13a-f 82

    3.1.5. Cc dn cht N1-(3-(hydroxyamino)-3-oxopropyl)-N4-

    phenylsuccinamid v N1-(2-(hydroxyamino)2-oxoethyl)-N5-phenyl

    glutaramid

    85

    3.1.5.1. Kt qu tng hp 85

    3.1.5.2. Kt qu phn tch ph ca cc dn cht 17a-c, f, h v 20a-h 93

    3.1.6. Tng hp N1-(4-clorophenyl)-N6-(3-(hydroxyamino)-3-oxopropyl)

    adipamid (26)

    97

    3.2. Hot tnh sinh hc 102

    3.2.1. Tc dng c ch HDAC 102

    3.2.2. Hot tnh khng t bo ung th in vitro 105

    3.2.3. Hot tinh khng t bo ung th in vivo 107

    CHNG 4. BN LUN 110

    4.1. Tng hp ha hc 110

    4.1.1. Tc nhn acyl ha l anhydrid acid 110

    4.1.2. Tc nhn acyl ha l acid carboxylic 111

    4.1.3. Tc nhn acyl ha l ester 117

    4.2. Khng nh cu trc 118

    4.2.1. Ph hng ngoi 118

    4.2.2. Ph khi lng 120

    4.2.2.1. Phn tch cm pic ion phn t 121

    4.2.2.2. C ch ph mnh ca phn t theo cu trc d kin 122

    4.2.3. Ph cng hng t ht nhn 126

    4.2.3.1. Ph cng hng t ht nhn ca cc acid hydroxamic mang

    khung benzothiazol

    126

    4.2.3.2. Ph cng hng t ht nhn ca cc acid hydroxamic mang

    vng phenyl

    134

    4.2.3.3. Ph cng hng t ht nhn ca acid hydroxamic mang vng

    thiazol

    137

    4.3. Hot tnh sinh hc 138

    4.3.1. Cc acid hydroxamic mang khung benzothiazol 138

    4.3.2. Cc acid hydroxamic mch alkyl c lin kt amid 143

  • vi

    4.3.3. Docking 147

    4.3.4. Hot tnh khng t bo ung th in vivo 148

    KT LUN V KIN NGH 151

    DANH MC CC CNG TRNH CNG B

    TI LIU THAM KHO

    PH LC

  • vii

    DANH MC CC K HIU, CH VIT TT

    (ppm) dch chuyn ha hc (phn triu) 13C-NMR Ph cng hng t ht nhn carbon 13 (13C-Nuclear Magnetic

    Resonance) 1H-NMR Ph cng hng t ht nhn proton (1H-Nuclear Magnetic Resonance)

    AcOH Acid acetic

    ADN Acid desoxyribonucleic

    AsPC-1 Dng t bo ung th ty ngi

    BCL2 B-cell lymphoma 2

    CBFb Core-binding factor subunit beta

    CBP Cyclic-AMP response element-binding protein

    CDI Carbonyl diimidazol

    CTPT Cng thc phn t

    DCC Dicyclohexyl carbodiimid

    DCM Dicloromethan

    DMEM Dulbeccos modified Eagle medium

    DMF Dimethylformamid

    DMSO-d6 Dimethylsulfoxid deutri ha

    ESI Ion ha phun bi in t (Electron Spray Ionization)

    FBS Huyt thanh bo thai b (Fetal bovine serum)

    FDA Cc qun l Thc phm v Dc phm m

    HAT Histon acetyltransferase

    HATU N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridin-1ylmethylen]-N-

    methylmethanaminium hexafluorophosphat

    HDAC Histon deacetylase

    HDIs Cc cht c ch HDAC

    HDLP Histone deacetylase-like protein

    HMBC Ph tng tc a lin kt d nhn

    HOBt 1-hydroxybenzotriazol

    HSQC Ph tng tc d nhn qua mt lin kt

    IC50 Nng c ch 50%

    IR Ph hng ngoi (Infrared Spectrometry)

    i Dch chuyn in tch

    J Hng s tng tc (Hz)

    MCF-7 T bo ung th v ngi

    MeOH Methanol

    MOZ Monocytic leukemia zinc-finger protein

  • viii

    MS Ph khi lng (Mass Spectrometry)

    MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromid

    NCI-H460 T bo ung th phi ngi

    PBS m phosphat (Phosphat buffered saline)

    PC-3 T bo ung th tin lit tuyn ngi

    PCl3 Phosphor triclorid

    PCl5 Phosphor pentaclorid

    POCl3 Phosphor oxyclorid

    PVDF Mng polyvinyliden difluorid

    rH Dch chuyn hydro

    RAR Receptor acid retinoic

    ROS Reactive oxygen species

    RPMI Mi trng nui cy t bo

    SAHA Acid suberoylanilid hydroxamic

    SDS-PAGE Gel SDS-PAGE (Sodium dodecyl sulfat polyacrylamid gel

    electrophoresis)

    Sin 3 Protein c ch phin m

    SMMHC T bo c (Smooth muscle myosin heavy chain)

    SW620 T bo ung th i trng ngi

    TSA Trichostatin A

    toC Nhit nng chy

    WAF1 Cht c ch kinase ph thuc cyclin

    ZBG Nhm gn ion Zn2+

  • ix

    DANH MC CC BNG

    TT Tn bng Trang

    1 Bng 1.1 Phn loi cc cht c ch HDAC 13

    2 Bng 1.2 Cc cht c ch HDAC v ang c th lm sng 19

    3 Bng 1.3 Tc dng c ch HDAC2 v c tnh t bo ca dn cht

    -alkoxy (AH10)

    28

    4 Bng 3.1 Kt qu phn tch ph khi ca cc cht 3a-f, 5a-f 64

    5 Bng 3.2 Kt qu phn tch ph 1H-NMR ca cc cht 3a-f, 5a-f 64

    6 Bng 3.3 Kt qu phn tch ph 13C-NMR ca cc cht 5a-f 66

    7 Bng 3.4 Kt qu phn tch ph khi ca cc cht 7a-f, 9a-h 73

    8 Bng 3.5 Kt qu phn tch ph 1H-NMR ca cc cht 7a-f, 9a-h 73

    9 Bng 3.6 Kt qu phn tch ph 13C-NMR ca cc cht 7a-f, 9a-h 75

    10 Bng 3.7 Kt qu phn tch ph khi ca cc cht 11a-d, 13a-f 82

    11 Bng 3.8 Kt qu phn tch ph 1H-NMR ca cc cht 11a-d, 13a-f 83

    12 Bng 3.9 Kt qu phn tch ph 13C-NMR ca cc cht 11a-d, 13a-f 85

    13 Bng 3.10 Kt qu phn tch ph khi ca cc cht 17a-c, f, h, 20a-h 93

    14 Bng 3.11 Kt qu phn tch ph 1H-NMR ca cc cht 17a-c,f,h,

    20a-h

    93

    15 Bng 3.12 Kt qu phn tch ph 13C-NMR ca cc cht 17a-c,f,h,

    20a-h

    96

    16 Bng 3.13 Tm tt kt qu tng hp cc dn cht trong lun n 98

    17 Bng 3.14 Tc dng c ch HDAC ca cc dn cht tng hp 102

    18 Bng 3.15 Kt qu nh lng tc dng c ch HDAC2 ca cc cht

    9a-h, 23

    104

    19 Bng 3.16 Kt qu th hot tnh khng t bo ung th ngi in vitro 105

    20 Bng 3.17 S thay i kch thc v khi lng ca khi u trn chut

    nhm th, nhm trng i chiu v SAHA

    107

    21 Bng 3.18 Phn trm thay i cn nng ca chut trong qu trnh th

    nghim

    108

    22 Bng 4.1 Cng cm pic ion phn t ca cht 7a 122

  • x

    TT Tn bng Trang

    23 Bng 4.2 D liu cc ph cng hng t ht nhn ca cht 9g 132

    24 Bng 4.3 D liu ph 1H-NMR v 13C-NMR ca cht 23 137

    25 Bng 4.4 Tc dng c ch HDAC v c tnh t bo in vitro ca cc

    cht 7a-f

    140

    26 Bng 4.5 Tc dng c ch HDAC v c tnh t bo in vitro ca cc

    cht 9a-h

    141

    27 Bng 4.6 Nng lng lin kt vi trung tm hot ng ca HDAC 147

    28 Bng 4.7 Kt qu c ch s pht trin khi u in vivo ca cht 9g

    cc liu khc nhau vi dng t bo ung th PC-3

    149

  • xi

    DANH MC CC HNH V, S

    HNH V

    TT Tn hnh Trang

    1 Hnh 1.1 S cu to nucleosom 3

    2 Hnh 1.2 HAT v HDAC iu ha qu trnh phin m 3

    3 Hnh 1.3 Phn loi HDAC ngi 7

    4 Hnh 1.4 Cu trc HDAC8 8

    5 Hnh 1.5 Cu trc v tr hot ng ca HDLP khi lin kt vi phn

    acetyl-lysin ca histon (tri) v Trichostatin A (phi)

    9

    6 Hnh 1.6 C ch phn ng deacetyl ha theo Finnin 9

    7 Hnh 1.7 iu ha s pht trin v sng st ca t bo bi cc cht

    c ch HDAC

    14

    8 Hnh 1.8 Cc cht c ch HDAC thc y s cht t bo 16

    9 Hnh 1.9 Cng thc c in ca HDI v v tr ca HDI trong ti

    enzym HDAC

    18

    10 Hnh 1.10 HDIs c cu trc peptid vng 20

    11 Hnh 1.11 HDIs l cc benzamid 21

    12 Hnh 1.12 HDIs l cc acid bo mch ngn 21

    13 Hnh 1.13 HDIs l cc dn cht ceton 22

    14 Hnh 1.14 HDIs c cu trc hydroxamat 23

    15 Hnh 1.15 Cc dn cht N-hydroxy-2-propenamid 24

    16 Hnh 1.16 a) Cc acid biphenyl-4-yl-acrylohydroxamic (AH2); b)

    Cc dn cht vi cu ni c hai lin kt i (AH3) v

    dng kh ha ca AH3 (AH4)

    25

    17 Hnh 1.17 Mt s dn cht c lin quan ca AH2b 25

    18 Hnh 1.18 Cc dn cht amid ngc ca SAHA 26

    19 Hnh 1.19 Cc aryloxyalkanoic N-hydroxyamid (AH9) 26

    20 Hnh 1.20 Cu trc ca amamistatin A, B 27

    21 Hnh 1.21 Cc dn cht -alkoxy ca SAHA 27

    22 Hnh 1.22 Cu trc ca dn cht p-methoxybenzyl ether (AH10) 28

  • xii

    TT Tn hnh Trang

    23 Hnh 1.23 Mt s dn cht -alkyl ca SAHA 29

    24 Hnh 1.24 Cc acid phenylthiazol hydroxamic tng t SAHA 29

    25 Hnh 1.25 Mt s acid phenylthiazol hydroxamic 30

    26 Hnh 1.26 Cc dn cht acid biphenyl-hydroxamic 30

    27 Hnh 1.27 Cc acid isoxazol-hydroxamic 31

    28 Hnh 1.28 ADS100380 32

    29 Hnh 1.29 Cc nh hng ti u ha cu trc ca ADS102550 32

    30 Hnh 1.30 Cc arylthiophen hydroxamat 33

    31 Hnh 1.31 Cc acid pyridin-thiophen-hydroxamic 33

    32 Hnh 1.32 Cc dn cht biphenyl sulfamid 34

    33 Hnh 1.33 Mt s dn cht sulfamid khc 34

    34 Hnh 1.34 Cc dn cht sulfamid khng mang cu ni amid 35

    35 Hnh 1.35 Mt s dn cht trithiocarbonat 35

    36 Hnh 1.36 Mt s trithiocarbonat khc v cht tng t 36

    37 Hnh 1.37 Cc dn cht thiol 36

    38 Hnh 1.38 T disulfid n KD5170 37

    39 Hnh 1.39 S thy phn v to chelat vi Zn2+ ca KD5170 37

    40 Hnh 1.40 a) Tng hp amid thng qua to ester hot ha; b) Mt s

    alcol hay dng

    44

    41 Hnh 3.1 Cng thc cu to ca 23 77

    42 Hnh 3.2 Cng thc cu to ca 26 98

    43 Hnh 3.3 Hnh nh khi u ca nhm th, nhm trng i chiu v

    SAHA

    108

    44 Hnh 4.1 Phn ng th i nhn acyl 110

    45 Hnh 4.2 Mt s hydroxylamin c gn nhm bo v 115

    46 Hnh 4.3 Cng thc cu to chung ca 51 cht tng hp c 118

    47 Hnh 4.4 Ph hng ngoi ca cht 5e 120

    48 Hnh 4.5 Ph khi lng ca cht 7a 121

    49 Hnh 4.6 Ph khi lng ca cht 20f 124

    50 Hnh 4.7 Ph 1H-NMR dn rng ca cht 5a 127

  • xiii

    TT Tn hnh Trang

    51 Hnh 4.8 Ph 1H-NMR dn rng ca cht 9f 128

    52 Hnh 4.9 a) Ph 1H-NMR; b) Ph 13C-NMR ca cht 9g 130

    53 Hnh 4.10 Ph tng tc n lng t d nhn HSQC ca cht 9g 130

    54 Hnh 4.11 Ph tng tc a lin kt d nhn - HMBC ca cht 9g 132

    55 Hnh 4.12 Ph 1H-NMR dn rng ca cht 20f 135

    56 Hnh 4.13 nh hng ca t trng flo ln carbon v hng s tng

    tc (J)

    136

    57 Hnh 4.14 Ph 13C-NMR dn rng ca cht 20b 136

    58 Hnh 4.15 Cu trc ca TSA v SAHA 138

    59 Hnh 4.16 Cng thc cu to ca cc acid hydroxamic 3a-f 139

    60 Hnh 4.17 Cc acid hydroxamic 5a-f, 7a-f 139

    61 Hnh 4.18 Kt qu phn tch Western blot ca cc cht 7a-f 139

    62 Hnh 4.19 Cu trc cc acid hydroxamic 9a-h 140

    63 Hnh 4.20 Kt qu phn tch Western blot ca cc cht 9a-f 141

    64 Hnh 4.21 Tng hp cc aryltriazolylhydroxamat 27a-d 142

    65 Hnh 4.22 Cu trc ca cc acid hydroxamic 11a-d v 13a-f 143

    66 Hnh 4.23 Cu trc ca cc acid hydroxamic 17a-c, f, h v 20a-h 144

    67 Hnh 4.24 Kt qu phn tch Western blot ca mt s cht i din

    dy 13 v 20

    144

    68 Hnh 4.25 Cu trc khng gian ca SAHA, 17a v 20a 145

    69 Hnh 4.26 Cu trc cc acid -lactam-hydroxamic 146

    70 Hnh 4.27 Cu trc chung ca cc dn cht homo-oxa-SAHA 146

    71 Hnh 4.28 Docking ca cht 9g (mu cam), 9h (mu tm hng) v

    SAHA (mu xanh l) vi HDAC8

    148

    72 Hnh 4.29 S thay i kch thc khi u trung bnh ca nhm th so

    vi SAHA

    149

    73 Hnh 4.30 S thay i cn nng ca chut trong qu trnh th nghim 150

  • xiv

    S

    TT Tn s Trang

    1 S 1.1 Phn ng to lin kt amid trc tip 39

    2 S 1.2 Phn ng to lin kt amid thng qua acid hot ha 40

    3 S 1.3 a) Phn ng to acyl clorid; b) Tng hp amid 40

    4 S 1.4 Vai tr xc tc ca pyridin 41

    5 S 1.5 Tng hp amid thng qua to acyl azid 41

    6 S 1.6 Tng hp amid s dng tc nhn hot ha CDI 42

    7 S 1.7 Tng hp amid s dng tc nhn hot ha DCC 43

    8 S 1.8 Tng hp amid s dng tc nhn hot ha ethyl

    cloroformat

    43

    9 S 1.9 Tng hp amid s dng tc nhn BOP 44

    10 S 1.10 Tng hp mt s dn cht amid ngc ca SAHA 45

    11 S 1.11 Tng hp acid biaryl hydroxamic 46

    12 S 1.12 Tng hp cc acid phenylthiazol hydroxamic 46

    13 S 3.1 Tng hp cc dn cht 3a-f, 5a-f 57

    14 S 3.2 Tng hp N1-(6-nitrobenzo[d]thiazol-2-yl)-N5-

    hydroxyglutaramid (5f)

    63

    15 S 3.3 Tng hp cc dn cht 7a-f v 9a-h 66

    16 S 3.4 Tng hp N1-(thiazol-2-yl)-N8-hydroxyoctandiamid (23) 76

    17 S 3.5 Tng hp cc dn cht 11a-d v 13a-f 77

    18 S 3.6 Tng hp cc dn cht 17a-c, f, h v 20a-h 86

    19 S 3.7 Tng hp N1-(4-clorophenyl)-N6-(3-(hydroxyamino)-3-

    oxopropyl)adipamid (26)

    97

    20 S 4.1 Tng hp cc cht trung gian 2a-f, 4a-f, 15a-c, 15f, 15h,

    18a-h

    110

    21 S 4.2 Tng hp cc acid hydroxamic 3a-f v 5a-f 111

    22 S 4.3 Tng hp acid hydroxamic 3a-f bng tc nhn hot ha

    DCC

    112

    23 S 4.4 Vai tr ca HOBt trong qu trnh to ester hot ha 113

  • xv

    TT Tn s Trang

    24 S 4.5 Tng hp 3a-f s dng tc nhn hot ha isobutyl

    cloroformat

    113

    25 S 4.6 Tng hp 3a-f s dng tc nhn hot ha CDI 114

    26 S 4.7 Tng hp acid hydroxamic 5f 115

    27 S 4.8 Tng hp cc ester trung gian ca cc dy cht 7, 9, 11,

    13, 17, 20 v cht 22

    116

    28 S 4.9 Tng hp ester trung gian 25 116

    29 S 4.10 Tng hp cc aryltriazolylhydroxamat 117

    30 S 4.11 Tng hp mt s dn cht -alkoxy ca SAHA 117

    31 S 4.12 C ch phn ng tng hp cc acid hydroxamic dy 7, 9,

    11, 13, 17 v 20, cht 23, 26 t ester

    117

    32 S 4.13 S ph mnh ca cht 7a 123

    33 S 4.14 S ph mnh ca cht 20f 125

  • 1

    T VN

    Nhng tin b trong cc ngnh khoa hc c bn nh di truyn hc, sinh hc

    phn t, sinh hc t bo v c bit l s ra i ca bn gen ngi gip cho cc

    nh khoa hc c nhng hiu bit su sc v khi u cp phn t cng nh cc qu

    trnh quyt nh s pht trin ca khi u. Do , hng lot cc protein ng vai tr

    quan trng trong ung th ng thi cng l ch m cc thuc iu tr ung th hng

    ti c pht hin nh cc protein kinase ph thuc cyclin, protein gy ung th

    Bcl-2, p53, cc farnesyltransferase, histon deacetylase (HDAC), telomerase,

    STAT[27]. Nh vy, vic nghin cu v pht trin thuc iu tr ung th theo

    phng php mi hin nay, phng php thit k cng thc da trn ch tc dng

    phn t, ngy cng t c nhiu thnh tu ng k.

    Mt trong nhng ch tc dng phn t ang c ch hin nay l cc histon

    deacetylase (HDAC). Nghin cu v cc HDAC xc nh hot ng bt thng ca

    HDAC c lin quan n nhiu bnh ung th. V vy, cc cht c ch HDAC ang tr

    thnh cc tc nhn chng ung th y trin vng. Acid suberoylanilid hydroxamic

    (Zolinza, 2006) v depsipeptid (Romidepsin, 2009) l hai cht c ch HDAC

    c Cc qun l thc phm v dc phm M (US-FDA) ph duyt trong iu tr u

    lympho da t bo T [21]. Bn cnh , mt s cht c ch HDAC khc cng ang

    c nghin cu v tri qua cc pha th lm sng nh NVL-LAQ824, MS-275, CI-

    994, PXD-101...[21,33,65]. Cc cht c ch HDAC c chia thnh 5 nhm da theo

    cu trc ha hc, trong cc dn cht acid hydroxamic c cc nh khoa hc trn

    th gii tp trung nghin cu nhiu nht do cu trc n gin d tng hp, hot tnh c

    ch HDAC mnh.

    Hi nhp vi xu hng nghin cu ca th gii v tm kim cht c ch HDAC

    c hot tnh khng t bo ung th tt, lun n Tng hp v th hot tnh sinh hc

    ca mt s dn cht acid hydroxamic hng c ch enzym histon deacetylase

    c thc hin vi 2 mc tiu:

    1. Thit k v tng hp c khong 40 - 50 dn cht acid hydroxamic mi

    hng c ch HDAC.

    2. Th tc dng c ch HDAC v tc dng khng t bo ung th ca cc cht

    tng hp c.

  • 2

    Chng 1. TNG QUAN

    1.1. HISTON DEACETYLASE

    Cc nghin cu v ung th xc nh cn nguyn ca bnh khng ch do c

    ch di truyn hc m cn do c ch di truyn biu hin gen. C ch di truyn biu hin

    gen lin quan n nhng thay i trong qu trnh biu hin gen m khng nh hng

    n cu trc chui ADN. C ch di truyn biu hin gen gm cc bin i v ADN v

    histon nh s methyl ha, acetyl ha [25,55,71,90]. Nhng bin i ny dn n cc

    bt thng ca qu trnh biu hin gen th hin s pht trin, s bit ha v s cht

    t bo theo chng trnh, kt qu l tng kh nng bin i ca t bo.

    Cho n nay, cc nghin cu chng minh cu trc ca nhim sc th l yu

    t quan trng trong iu ha qu trnh biu hin gen [11,22,63,71]. Cu trc ca nhim

    sc th l mt phc hp cu to bi ADN, cc histon v cc protein khng phi histon

    [22,40]. Histon l cc protein c bn giu acid amin nh lysin, arginin, c chia

    thnh 5 nhm chnh (H1, H2A, H2B, H3, H4). Tng cp ca H2A, H2B v H3, H4

    cng nhau to nn li protein octomer hnh a. Li protein ny c qun quanh bi

    146 cp ADN to nn nucleosom (hnh 1.1) [11,22,63,71,77]. Cc nucleosom ni vi

    nhau nh phn amino tn ca cc histon. Bn cp histon li c 2 phn quan trng:

    phn ui C nm bn trong li ca nucleosom v phn u N vi acid amin kt thc l

    lysin nm bn ngoi nucleosom [63]. Cu trc ny chu nh hng chnh bi s bin

    i phn u N ca histon. Phn u N ca histon, c bit H3, H4 l ni din ra rt

    nhiu qu trnh bin i khc nhau trong phin m nh acetyl ha/deacetyl ha lysin,

    methyl ha lysin v arginin, phosphoryl ha serin v ubiquinin, sumoyl ha lysin

    [22,40,71].

    C ch ca phn ln cc bin i trn u cha sng t. So vi s methyl ha

    v phosphoryl ha, dng nh s acetyl ha phn li histon l qu trnh bin i

    c nghin cu v hiu bit tng tn hn. Histon c th tn ti mt trong hai dng

    i lp nhau l acetyl ha hoc deacetyl ha. Cc enzym ng vai tr trong s chuyn

    i ny l histon acetyltransferase (HAT) v histon deacetylase (HDAC)

    [11,22,40,63,71]. Khi xy ra s acetyl ha histon, nhim sc th s c tho xon v

    hot ha qu trnh phin m, trong khi deacetyl ha phn u N ca histon s lm

    gim qu trnh phin m thng qua s ng xon nhim sc th. Ni chung, khi tng

    acetyl histon dn n thc y qu trnh phin m v ngc li khi s acetyl ha histon

    gim lm ngn cn qu trnh phin m (hnh 1.2) [63,71].

  • 3

    Hnh 1.1. S cu to nucleosom [71]

    Hnh 1.2. HAT v HDAC iu ha qu trnh phin m [71]

    * Ch thch: HAT: histon acetyltransferase; HDAC: histon deacetylase; Ac: acetyl.

  • 4

    1.1.1. Histon acetyltransferase (HAT)

    Histon acetyltransferase (HAT) xc tc chuyn nhm acetyl t acetyl coenzym

    A n lin kt vi nhm -amino ca lysin phn u N ca histon. S chuyn i

    ny xy ra nhiu hn trn histon H3, H4. V tr acetyl ha quan trng l Lys9 v Lys14

    trn histon H3; Lys5, Lys8, Lys12 v Lys16 trn histon H4 [71,77]. S acetyl ha histon

    lm tho xon nhim sc th bng cch trung ha in tch dng ca phn u N ca

    histon, do vy lm gim i lc ca histon vi phn tch in m trn ADN [70]. Chnh

    v vy, vic tng acetyl ha histon lm ni lng cu trc nhim sc th v hot ha

    gen.

    Cc histon acetyltransferase c chia thnh 5 nhm bao gm khong 20

    isoenzym [15,22,40,70]. C s ca vic phn nhm ny l da trn s tng t nhau

    ca cu trc chui c bn v thng c c cht c hiu. Nhm HAT u tin l cc

    GNAT (Gcn5-related N-acetyltransferase), bao gm cc protein lin quan n s bt

    u phin m, nh l Gcn5 v PCAF (p300/cyclic-AMP-response-element binding

    protein-associated factor). Nhm th hai l cc MYST, c t tn theo protein gn

    Zn trong bnh bch cu n nhn to (MOZ-monocytic leukemia zinc-finger protein),

    YBF2/SAS3, SAS2 v HIV-1 TAT-interactive protein 60 (TIP60). Nhm th ba l 2

    enzym lin quan cht ch n protein p300 v CBP (cyclic-AMP response element-

    binding protein), chng hot ng nh cht ng hot ha mt s phc hp ca nhn

    t sao chp m. Hai nhm HAT khc l cc cht ng hot ha receptor nhn nh

    phc hp TFIID (general transcription factor IID) (cu trc di phn t l TAFII250)

    v ACTR (amplified in breast cancer), SRC1 (avian sarcoma viral oncogene

    homologue 1) [20]. Khng ch acetyl ha ui histon, cc HAT cn c th acetyl ha

    cc cht ng hot ha, cht ng c ch sao chp m nh E2F, p53, GATA1 [40,76].

    Nh vy, cc HAT ng vai tr quan trng trong hot ha cng nh c ch gen. Cc

    HAT khng gn kt trc tip vi ADN m to thnh phc hp vi cc HAT khc cng

    nh vi cc nhn t sao chp m.

    1.1.2. Histon deacetylase (HDAC)

    Histon deacetylase c tc dng ngc vi HAT, n xc tc vic loi b nhm

    acetyl ca lysin phn u N ca histon, dn n nhim sc th b ng xon v c

    ch qu trnh phin m [22,40,43,63,71,81]. HDAC c bo tn trong qu trnh tin

    ha v biu hin trong cc t chc ca cc sinh vt t n bo nguyn thy cho n

    loi ngi.

  • 5

    Tng t nh HAT, cc HDAC khng gn kt trc tip vi chui ADN m to

    phc hp vi cc cht ng c ch phin m khc. Cc HDAC khc nhau to cc phc

    hp khc nhau. Hot tnh ca HDAC c iu ha bi s bin i sau phin m. Cc

    HDAC khng ch deacetyl ha histon, m cn deacetyl ha cc protein khng histon

    nh p53, Ku70, pRB v E2F-1 [16,59,81].

    1.1.2.1. Phn loi

    HDAC1 ngi l histon deacetylase u tin c xc nh bng cch s

    dng cht c ch HDAC trapoxin vo nm 1996 [80]. Cho n nay, 18 HDAC khc

    nhau ngi c xc nh v chia thnh 4 nhm (hnh 1.3) [11,22,33,34,40,56,71,

    89]. Cc HDAC khc nhau tnh tng ng chui, c cht c hiu v cofactor ph

    thuc [33,34,89].

    * Nhm I (HDAC1, 2, 3, 8) (hnh 1.3): tng ng vi Rdp3 t bo nm men

    S.cerevisiae, c chc nng c ch phin m, ch hot ng khi nm trong phc hp

    protein [2,16]. HDAC nhm I c nm men, ng vt c v v thc vt. ng vt

    c v, cc HDAC ny c chia thnh 2 phn nhm l HDAC1/2 v HDAC3.

    Cu trc ca HDAC1 v 2 kh tng ng (82%). Vng xc tc nm u N

    to nn phn chnh ca protein. Khi c to ra bng k thut ti t hp, HDAC1 v 2

    khng c hot tnh chng t cc cofactor l cn thit cho hot ng ca HDAC.

    HDAC1, 2 hot ng khi nm trong phc hp nh phc hp SIN3, NuRD/NRD/Mi2

    v CoREST. Phosphoryl ha serin trn HDAC1, 2 iu ha hot ng ca chng v

    to nn phc hp vi cc cofactor khc [29,71].

    HDAC3 c tm thy trong phc hp vi N-CoR (nuclear receptor copressor)

    v phc hp vi SMRT (silencing mediator for retinoic acid and thyroid hormon

    receptors). HDAC3 c cng cu trc vng ging nh cc HDAC nhm I. Khong 68%

    vng cc acid amin ca HDAC3 ng nht vi HDAC1, 2. Phn ui C khng o

    ngc ca HDAC3 cn thit cho c hot tnh deacetyl ha v c ch phin m [71].

    HDAC8 khng c xp vo phn nhm no v n ch yu c ng vt c

    xng sng. HDAC8 c 37% tng ng vng cc acid amin vi HDAC3. Hot ng

    ca HDAC8 gim khi phosphoryl ha bi protein kinase A, trong khi HDAC1, 2 li

    hot ng bi s phosphoryl ha [30]. HDAC8 l HDAC u tin ng vt c v

    xc nh c cu trc 3 chiu [74].

    * Nhm II gm HDAC4, 5, 7, 9 (nhm IIa) v HDAC6,10 (nhm IIb) tng ng vi

    HDA1 trong t bo nm men (hnh 1.3). HDAC nhm II c kch thc phn t ln

    (855-1122 aa) v khc bit so vi HDAC nhm I do c u N tham gia vo qu trnh

    c ch phin m. Nhm ny cha tn hiu nh v ngoi nhn NES nn c th di

    chuyn t nhn ra bo tng v ngc li.

  • 6

    Hn 70% vng cc acid amin ca HDAC4, 5 tng ng vi nhau, cn

    HDAC7 ch tng ng khong 57 - 58% vi HDAC4, 5. C 3 HDAC ny u c

    vng xc tc nm ui C ca protein. Trong khi , HDAC9 li c vng xc tc

    u N, ging nh cc HDAC nhm I. Cc HDAC nhm IIa c u N tng tc c

    hiu vi yu t phin m MEF2 (myogenic transcription factor 2). Yu t ny ng vai

    tr quan trng trong s bit ha c. Do vy, cc HDAC ny khi kt hp vi MEF2 gy

    c ch chc nng phin m ca MEF2, h qu l t bo c khng bit ha c. Cc

    HDAC ny c th b sung cho nhau kim sot s iu ha bit ha ca qu trnh

    biu hin gen trong cc giai on khc nhau ca s bit ha trong t bo c [71].

    HDAC6 v 10 c vng acid amin tng ng khong 37%. im khc bit ca

    HDAC6 v 10 so vi cc HDAC khc l chng c 2 vng xc tc, tuy nhin HDAC10

    c 1 vng xc tc b bt hot. Mt c im ring ch c HDAC6 l s c mt ca

    HUB (HDAC6-, USP3- v Brap2-related zinc finger motif) ui C. c im ny l

    du hiu cho s ubiquitin ha v cho thy HDAC ny thin v s thoi ha. Nghin

    cu in vitro v in vivo xc nh HDAC6 lin quan cht ch n cc bnh thoi ha

    m thn kinh nh bnh Parkinson, bnh Hutington. HDAC6 ch yu c bo tng,

    tuy nhin n cn c tm thy nhn trong phc hp vi HDAC11. HDAC10 c mt

    vng xc tc u N v vng xc tc b bt hot ui C. HDAC 10 c kh nng

    tng tc vi HDAC1, 2, 3, 4, 5, 7, nhng khng tng tc vi HDAC6 v vn th

    hin hot tnh deacetyl ha khi khng to phc. HDAC6, 10 khng li trapoxin v

    butyrat natri tt hn cc HDAC nhm I, IIa. [21,45,71].

    * Nhm III: (silent information regulator genes - Sirtuins), gm SIRT1-7 tng t

    Sir2 t bo nm men. HDAC nhm III ny khng lin quan n cc nhm khc,

    chng c trong nhn (SIRT1,6,7), bo tng (SIRT2) hoc ty th (SIRT3,4,5).

    HDAC nhm III t c nghin cu ngi, nhng c xc nh c c ch hot

    ng ph thuc vo cofactor NAD+, khc vi HDAC nhm I, II, IV (HDAC kinh in)

    ph thuc Zn2+ v b c ch bi cc cht to phc chelat vi Zn2+ [45,71,89].

    * Nhm IV: HDAC 11 (ch c ngi). Nghin cu h thng loi thy rng HDAC11

    lin quan gn hn vi HDAC3, 8, nn c th gi nh HDAC11 lin quan mt thit vi

    HDAC nhm I hn l nhm II. HDAC 11 c vng xc tc u N v c th b c ch

    bi trapoxin (dn cht ca TSA). HDAC11 cha c tm thy trong cc phc hp

    HDAC bit c th xc nh chc nng sinh hc [45,71,89].

  • 7

    Hnh 1.3. Phn loi HDAC ngi [21]

    * Ch thch: Hnh ch nht mu xanh dng l vng xc tc c bo tn ca HDAC; N:

    nhn; C: bo tng; Mit: ty th; Ac: acetyl ha; P: phosphoryl ha; S: sumoyl ha; Ub:

    ubiquitin ha. N.D: cha xc nh.

    HDAC khng ch iu ha cc protein histon m rt nhiu protein khng histon

    cng b nh hng bi hot tnh ca cc HDAC. Thut ng cc cht c ch HDAC

    ch cc cht c kh nng c ch HDAC nhm I, II v IV [45,89].

    1.1.2.2. Cu trc ca HDAC v c ch phn ng deacetyl ha

    Vic xc nh cu trc ca HDAC rt cn thit xc nh c ch tc dng ca

    HDAC, ng thi da vo cu trc HDAC thit k cng thc cho cc cht c ch

    HDAC. Phng php kt tinh to tinh th v chp tia X c p dng tm ra cu

    trc tinh th ca cc HDAC khc nhau, c bit l trung tm hot ng ca n.

    HDAC8 l HDAC u tin ng vt c v xc nh c cu trc 3 chiu [74].

  • 8

    Hnh 1.4. Cu trc HDAC8 ( ion Zn2+ biu th l hnh trn mu xanh l) [86]

    Cc HDAC u c trung tm hot ng gm 2 phn chnh: ion Zn2+, knh

    enzym dng ti hnh ng. Bao quanh ion Zn2+ l 2 cp acid amin Histidin-Aspartic

    (HDLP l His131-Asp166 v His132-Asp173, HDAC 8 l His142-Asp176 v His143-

    Asp183), mt phn t Tyrosin ng vai tr cho proton (HDLP l Tyr297, HDAC8 l

    Tyr306) v 2 acid aspartic (HDLP l Asp258 v Asp168, HDAC8 l Asp178 v

    Asp267), mt phn t Histidin (HDLP l His170, HDAC8 l His180) [11].

    - Ion Zn2+ l coenzym ca HDAC, nm y knh enzym. Trong phn t HDAC,

    ion Zn2+ c th to 5 lin kt phi tr: 4 lin kt vi nguyn t oxy, nit ca cc acid

    amin, 1 lin kt phi tr vi nguyn t oxy ca nhm acetyl ca phn t acetyl-lysin

    phn u N ca histon, t xc tc tch loi nhm acetyl. Khi c mt cc cht c ch

    HDAC nh cc acid hydroxamic, ion Zn2+ to 2 lin kt phi tr vi 2 nguyn t oxy

    ca nhm hydroxamic (hnh 1.5) [11].

    - Knh enzym c dng ti hnh ng hp, to nhiu lin kt Van der Waals vi c

    cht (lysin tn ca histon/phn cu ni ca cc cht c ch HDAC). Ti c cu to

    t cc acid amin thn lipid: Phenylalanin, Tyrosin, Prolin, Histidin. y ti cn c 1

    vi phn t nc lm nhim v vn chuyn nhm acetyl trong phn ng deactyl ha v

    tham gia to lin kt hydro khi khng c mt nhm -OH ca Tyrosin. Cu trc ti rt

    linh ng, c th bin i ph hp vi chiu di ca cc c cht khc nhau. B rng

    ca ti c gii hn bi 2 vng thm c tm thy trn cng mt v tr nhiu

    HDAC khc nhau. Trn ming ti c 1 vnh nh c to nn t 1 vi vng xon

    protein (phn vnh s tng tc vi nhm nhn din b mt ca HDAC) [11].

  • 9

    Hnh 1.5. Cu trc v tr hot ng ca HDLP khi lin kt vi phn acetyl-lysin ca

    histon (tri) v Trichostatin A (phi) [13]

    Finnin l ngi u tin nghin cu chi tit tng tc gia cht c ch HDAC

    v enzym HDAC nm 1999 [27]. Nghin cu s dng HDLP (histone deacetylase like

    protein), mt cht ng ng phn lp t vi khun Aquiflex aeolicus. HDLP c vng

    acid amin tng ng 30% vi HDAC1 [11].

    Hnh 1.6. C ch phn ng deacetyl ha theo Finnin [11,27]

    u tin, nguyn t oxy ca nhm carbonyl ca phn N-acetyl lysin trn u N

    ca histon lin kt phi tr vi Zn2+, lm nhm carbonyl phn cc v pha oxy v

  • 10

    carbon tr nn i in t hn. Mt phn t nc s to lin kt phi tr vi Zn2+. Nh

    h thng chuyn tip Asp173 - His132 v Asp166 His131, nguyn t oxy ca nc

    tr nn i nhn hn. Sau khi c hot ha, oxy ca nc tn cng vo nguyn t C

    ca nhm carbonyl to ra oxyanion t din trung gian (oxy ca nhm carbonyl), c

    n nh bi Tyr297 v Zn2+. Cui cng lin kt C-N b b gy, 1 proton c chuyn

    t His132 cho nguyn t nit to thnh acetat v lysin [11].

    1.1.3. Mi lin quan gia ung th v s bt thng hot ng ca HAT hoc

    HDAC

    Rt nhiu bnh c nguyn nhn do s bin i bt thng di truyn biu hin

    gen (epigenetic) cng nh t bin gen, c bit l bnh ung th.

    HAT acetyl ha histon lm trung ha cc dng trn lysin v gip tho xon

    cu trc ca nucleosom, do gip cho cc nhn t sao m d dng tip cn ADN.

    Ngc li, cc HDAC xc tc loi b nhm acetyl t histon v protein khng phi

    histon, lm tng s tch in dng trn u N ca histon v ng xon nhim sc th,

    kt qu l c ch qu trnh phin m do ngn cn cc nhn t sao m tin n ch ca

    chng trn ADN. Nh vy, s acetyl ha v deacetyl ha nhim sc th ng vai tr

    quan trng trong iu ha qu trnh biu hin gen. Vic mt cn bng hot ng gia

    HAT v HDAC c th dn n nhng bt thng biu hin gen v do dn n ung

    th [21,40,45,56,63].

    Hot ng ca HAT lin quan n s di chuyn, xm ln, s biu th qu mc

    hoc s t bin trong rt nhiu loi ung th k c ung th mu v ung th biu m.

    Hai HAT b bin i r nht trong mt s bnh ung th do t bin hoc di chuyn l

    p300 v CBP. S t bin v ct on ca p300 c chng minh trong mt s

    bnh nh u m thn kinh (glioblastommas), ung th carcinoma gan (hepatocellular

    carcinomas), bnh bch cu. Hi chng Rubinstein Taybi, c xu hng pht trin

    thnh ung th, lin quan n s t bin ca CBP [31,70]. Ngoi ra, CBP c tm

    thy dng phi hp vi MOZ trong bnh bch cu ty bo cp (AML).

    Tng t, cc HDAC cng c xc nh b ri lon iu ha trong ung th. S

    huy ng bt thng ca cc HDAC vo chui iu ha ca gen ch c th xy ra

    thng qua tng tc bin i ca chng vi vic tng cng vai tr ca cc protein gn

    kt ADN gy ung th. V d nh receptor RAR gn kt gen PML (promyelocytic

    leukemia gene) hoc PLZF (promyelocytic leukemia zinc finger) trong bnh bch cu

    tin ty bo cp (APL). Trong iu kin sinh l, RAR l nhn t sao m hot ha

    acid retinoic gip gii phng phc hp ng c ch cha HDAC v lm gia tng cc

  • 11

    cht ng hot ha sao m (bao gm c HAT). iu ny dn n s acetyl ha histon

    v c ch gen y mnh s bit ha t bo. Trong bnh bch cu tin ty bo cp

    (APL), protein gn kt RAR/PML hoc RAR/PLZF gi HDAC v phi hp vi

    phc hp ng c ch. Do tng methyl transferase histon v ADN, dn n ngn

    cn s phin m [21,26,40]. Do vy, t bo ung th khng tri qua giai on bit ha

    v pht trin qu mc. S gia tng bt thng ca HDAC cn c quan st khi gen

    t bin gy ung th Bcl6 c biu th qu mc trong bnh u lympho t bo B [9].

    Tng t, protein gn kt AML1-ETO tm thy trong bnh bch cu ty bo cp

    (AML) c chc nng nh cht c ch sao m ch yu thng qua ETO, do vy c vai

    tr nh v tr gn kt cho phc hp ng c ch N-Cor/Sin3/HDAC1. Vic chuyn i

    AML1 t cht hot ha phin m thnh cht c ch c iu khin bi protein gn

    kt CBFb-SMMHC thng qua s gia tng phc hp ng c ch mSin3A/HDAC.

    Cui cng, biu th qu mc nhn t sao m SCL/Tal1 trong bnh u lympho t bo T

    cp c nguyn nhn l do gia tng bt thng HDAC1 nm trong phc hp ng c

    ch, dn n ngn cn gen ch iu ha E47/HEB [18]. Biu th qu mc HDAC1

    v/hoc HDAC2 v/hoc HDAC6 cn gp trong mt s bnh ung th tng c nh

    ung th tin lit tuyn, ung th d dy, trc trng, ung th v v ung th no

    [35,75,88] cng nh trong cc bnh l c tnh v mu (bnh bch cu ty bo cp,

    bch cu t bo B, bnh u lympho t bo T ngoi vi, bnh u lympho t bo B v bnh u

    lympho da t bo T) [62]. Hn na, vic tm ra cc c cht ca HDAC l cc protein

    nh p53, E2F, Rb, Bcl6, Gli1 lin quan n xu hng gy ung th v tin trin bnh

    ung th khng nh vai tr ca HDAC trong ung th [16,59,61]. Tm li, cc bin

    i sau phin m ca HDAC c th lm thay i tng tc ca chng vi phc hp

    ng c ch m cc phc hp ny lin quan n qu trnh phin m ca cc gen gy

    ung th.

    Nh vy, c ch phin m c iu ha bi s gia tng HDAC v c th kim

    sot ung th bng cch c ch hot ng ca HDAC. y chnh l mt trong mc tiu

    phn t hp dn cho chin lc iu tr ung th. Cc cht c ch HDAC v ang

    c nhiu nh khoa hc trn th gii nghin cu nhm tm ra cht c tc dng c ch

    chn lc tng loi HDAC ng dng trong iu tr ung th.

    1.2. CC CHT C CH HDAC (HDIs)

    1.2.1. Phn loi

    Nm 1990, Yoshida v cng s pht hin ra dn cht hydroxamat t nhin

    u tin c tc dng c ch trc tip HDAC l Trichostatin A (TSA), vn l cht c

  • 12

    tc dng chng nm [91]. Sau , da trn nhng hiu bit v mi lin quan gia

    HDAC v ung th ng thi xc nh c cu trc 3D ca cc HDAC, mt s cht

    c ch HDAC c nghin cu v th nghim trn lm sng ng dng trong

    iu tr ung th. Cho n nay, nhiu cht c ch HDAC (HDIs) c cng b.

    Chng c th c ngun gc thin nhin hay tng hp ha hc. FDA ph duyt 2

    cht c ch HDAC c s dng trong iu tr u lympho da t bo T l vorinostat

    (2006), v depsipeptid (2009). y chnh l ngun ng lc thc y cc nh nghin

    cu tip tc tm ra cc cht c ch HDAC mi.

    HDIs c chia thnh 5 nhm chnh da trn cu trc ha hc: cc acid

    hydroxamic, cc peptid vng, cc acid bo, benzamid v cc dn cht ceton (bng 1.1).

  • 13

    Bng 1.1. Phn loi cc cht c ch HDAC [22]

    Cht Cu trc Cht Cu trc

    Cc acid hydroxamic

    TSA (Trichostatin A)

    NHOH

    O

    N

    O

    Oxamflatin

    O

    NHOHHN

    S

    O

    O

    Acid

    suberoylanilid

    hydroxamic (SAHA)

    HN

    NHOH

    O

    O

    NVP-LAQ-

    824

    HN

    NHOH

    O

    O

    N

    OH

    HN

    CBHA (Acid M-carboxycinnamic

    bishydroxamid)

    HN

    NHOH

    O

    O

    HOHN

    O

    Acid

    sulfonamid

    hydroxamic Scriptaid

    Peptid vng

    Depsipeptid

    (FK-228)

    HN

    O CH3

    HN

    O

    H3C

    CH3

    O

    NH

    O

    CH3

    CH3

    OHN

    O

    S

    S

    Acipidin

    CHAP

    Benzamid

    MS-275 N

    O

    O

    NH H

    N

    O

    NH2

    CI-994

    Cc acid bo

    Acid valproic

    O

    OH

    Phenyl

    butyrat O

    ONa

    Cc dn cht ceton

    Trifluoromethyl

    ceton

    Alpha-

    cetoamid

  • 14

    Mi nhm c nhng hn ch ring: cc acid hydroxamic b chuyn ha nhanh

    v c ch khng chn lc cc HDAC; cc benzamid v cc acid bo c hiu lc hn

    ch; dn cht ceton b kh ha trong huyt tng; trong khi cc peptid vng c cu

    trc qu phc tp [41].

    1.2.2. C ch tc dng ca cc cht c ch HDAC

    Cc cht c ch HDAC c tc dng chng ung th do tc ng ln nhiu giai

    on quan trng ca chu trnh t bo lm mt s iu ha trong t bo c tnh. Trong

    , yu t then cht quyt nh hot tnh chng ung th ca HDIs l thc y s bit

    ha, c ch chu trnh t bo v thc y s cht t bo. Ngoi ra, hot ha p ng

    min dch v c ch s to mch cng l vai tr rt quan trng ca HDIs, gin tip c

    ch s pht trin in vivo ca khi u (hnh 1.7) [3,40].

    Hnh 1.7. iu ha s pht trin v sng st ca t bo bi cc cht c ch HDAC

    [40]

    * Cc cht c ch HDAC thc y s bit ha

    Khi s dng n c, cc cht c ch HDAC thc y bit ha v ngng tng

    sinh t bo cc bnh bch cu v cc khi u tng c. c ch chu trnh t bo l vic

    cn thit trong s bit ha t bo. Phn tch cc kiu chu trnh t bo ca t bo ung

    th c tip xc vi cc cht c ch HDAC cho thy cc t bo thng b ngng

    li pha G1, nhng i khi li tch t trong t bo n pha G2 ca chu trnh t bo

    (hnh 1.7) [40,57].

    V d trong bnh bch cu tin ty bo cp (APL), cc cht c ch HDAC c

    th hip ng tc dng vi acid retinoic thc dy s bit ha in vitro v in vivo ca

  • 15

    protein gy ung th PLZF-RAR. S bit ha t bo ty ph thuc vo RAR

    (receptor acid retinoic) hot ha qu trnh phin m v cc protein gy ung th PLZF

    RAR cn tr chng trnh bit ha bnh thng. Qu trnh tng t c th xy ra

    trong bnh bch cu ty bo cp (AML). Cc cht c ch HDAC c ch chc nng ca

    cc protein gn kt AML1-ETO v TEL-AML1, khi phc s nhy cm ca cc t bo

    c tnh vi acid retinoic. Ngoi ra, cc cht c ch HDAC c th gy bit ha nhiu

    loi t bo, nhng qu trnh ny vn cha c bit r [40].

    Hu ht cc cht c ch HDAC c kh nng hot ha qu trnh phin m gy ra

    bi cht c ch kinase ph thuc cyclin (cyclin-dependent kinase inhibitor), l WAF1

    (cn gi l CIP1, p21; c m ha bi v tr gen CDKN1A). WAF1 c th c ch

    cyclin E-CDK2 v cyclin A-CDK2. S c mt ca CDKN1A cn thit cho cc cht c

    ch HDAC thc y s ngng pha G1. S tip xc ca cc t bo thiu ht

    CDKN1A vi cc cht c ch HDAC dn n tch t cc t bo c ADN a bi v lm

    cho cc t bo ny nhy cm vi s cht t bo. S phi hp hot ng ca cc cyclin,

    cc CDK (cyclin-dependent kinase), nhng cht c ch CDK v cc thnh vin RB

    (retinoblastoma protein) rt cn thit cho s bit ha ca nhiu h thng [40].

    Sau khi tip xc vi HDIs, thng thng cc t bo ung th dng li pha G1

    sao chp ADN, sau i vo s cht t bo. Nhng mt s t bo ung th li tch t

    n im kim sot G2 (G2 checkpoint), v tr m ti chu trnh t bo tm thi dng

    li, ch n khi cc iu kin tr nn ph hp th chu trnh li tip tc. Nhng t bo

    bnh thng tri qua im kim sot G2 (G2 checkpoint) v tip tc pht trin, trong

    khi nhng t bo ung th ti to ADN thnh dng ADN a bi (4nADN) v chuyn

    sang giai on gy cht t bo theo chng trnh. Tuy nhin, c ch phn t cht c

    ch HDAC thc y G2 checkpoint vn cn cha sng t. C th trong mt s t bo,

    HDIs thc y trc tip hoc gin tip gen hot ha im kim sot G2 (G2

    checkpoint) [40].

    * Cc cht c ch HDAC gin tip gy ra s cht t bo theo chng trnh

    Cc t bo ung th khc nhau sau khi c tip xc in vitro vi cc cht c ch

    HDAC c th dn n s cht t bo theo chng trnh. S cht t bo l mt chng

    trnh cht sinh l ca t bo kim sot s lng cc t bo bnh thng trong sut

    qu trnh pht trin v bnh tt. Hin nay xc nh c hai con ng gy cht t

    bo v c hai con ng u c s tham gia ca cc enzym cystein protease (cc

    caspase) (hnh 1.8) [33,40].

    Con ng th nht c hot ha bi cc receptor gi l cc death-receptor

    nh CD95, receptor TNF (tumour-necrosis factor) v receptor TRAIL (TNF-related

  • 16

    apoptosis-inducing ligand). Cc yu t ny sau khi gn vi cc phi t bt u hot

    ha cc caspase gn mng t bo (caspase-8 v -10). Cc caspase ny sau s hot

    ha cc caspase kch thch (caspase-3 v -7) v dn n s cht t bo.

    Con ng th hai cn c s ph v mng ty th, gin tip gii phng

    cytochrom c, cc protein h tr s cht t bo khc (nh SMAC/DIABLO (the second

    mitochondria-derived activator of caspase), HTRA2 (high temperature requirement 2)

    v yu t thc y s cht t bo (AIF)) v s hot ha caspase-9 thng qua yu t

    hot ha protease gy cht t bo (APAF1). S ton vn ca mng ty th c kim

    sot bi cc protein trong h protein BCL2 (bao gm cc protein h tr s cht t bo

    (BAX, BAK) v cc protein khng li s cht t bo (BCL2, BCL-XL) [33,40].

    Hnh 1.8. Cc cht c ch HDAC thc y s cht t bo [40]

    * Ch thch: thnh phn c ch s cht t bo c mu vng, thnh phn y mnh s cht t

    bo c mu tm.

    Cc cht c ch HDAC c ghi nhn c kh nng hot ha c receptor gy

    cht t bo v qu trnh cht t bo ni sinh (hnh 1.8). V d, apicidin v CBHA c

    th kch thch biu hin ca CD95 v gc kt hp CD95 (CD95L). Tuy nhin, butyrat

    lm cho t bo nhy cm vi s cht t bo gin tip bi CD95 m khng thc y s

    phin m ca gc kt hp hay receptor. Depsipeptid c ch s biu hin CD95L sau

    khi hot ha t bo T v ngn cn s cht t bo T sau . V vy, qu trnh death-

  • 17

    receptor c th quan trng cho s cht t bo gy ra bi cc cht c ch HDAC, ph

    thuc vo loi t bo v nhm cht c ch HDAC c s dng.

    Vic biu hin qu mc ca BCL2 (yu t ngn cn qu trnh cht t bo ni

    sinh) trong khi qu trnh death-receptor cn nguyn vn cng vi kh nng c ch s

    cht t bo gin tip bi cc cht c ch HDAC cho thy tm quan trng ca cc qu

    trnh ni sinh i vi vai tr ca cc cht c ch HDAC. Nhng d kin ny c

    chng minh bng vic pht hin ra s cht t bo do cc cht c ch HDAC trng

    khp vi s tng cng cc protein BCL2 h tr s cht t bo (BAX, BAK) v s

    gim cc protein h BCL2 khng li s cht t bo (BCL2, BCL-XL) [40]. Cc cht c

    ch HDAC c th vn gy ra s cht t bo khng km theo hot ha caspase. SAHA

    hot ha qu trnh cht t bo ni sinh bng cch thc y b gy lin kt v hot ha

    cht ch vn s cht t bo tng tc vi BH3 (BID), dn n ph v mng ty th v

    to thnh cc dng oxy hot ng (ROS). Ngc li, cc cht c ch ROS ngn cn s

    cht t bo do SAHA [40].

    * Cc tc dng khc lin quan n c ch khng ung th ca cc cht c ch

    HDAC

    Ngoi tc dng trc tip ln s pht trin v sng st ca t bo ung th, cc

    cht c ch HDAC cn tc dng gin tip n s pht trin khi u. Cc cht c ch

    HDAC c th hot ha phc hp ha hp m (MHC) nhm I v II lin quan n phin

    m, nhng phn t ng kch thch CD40, CD80 v CD86, phn t gn vo khong

    gian bo ICAM1, v cc interferon loi I v II, nhm lm tng s nhn dng v hot

    ha ca cc t bo min dch (hnh 1.7) [40]. Hn na, s pht trin v sng st ca

    ung th tng c pht trin nhanh i hi s hnh thnh mch trong khi u duy tr

    cung cp lin tc oxy v cht dinh dng. Trichostatin A (TSA) c th c ch s biu

    hin gim oxy m ca yu t pht trin mng trong mch mu (VEGF) v ngn cn s

    to mch c in vitro v in vivo. V vy, tng cng p ng min dch v c ch s to

    mch ca khi u c th ngn cn r rt s pht trin khi u ban u v s di cn [40].

    1.2.3. Cu trc ca cc cht c ch HDAC

    Cc HDIs c chia thnh nhiu nhm khc nhau nhng c mt s c im

    chung v mt cu trc, bao gm 3 phn chnh [3,6,17,58]:

    - Nhm gn vi ion Zn2+ (A - Zinc Binding Group, ZBG): nh acid hydroxamic,

    thiol, nhm o-aminoanilin ca benzamid, -cetoester, ceton thn du... quyt nh tnh

    c hiu v hiu lc ca HDIs.

    - Vng cu ni s nc (B): thng l mch hydrocarbon thn du c th to nhiu

  • 18

    lin kt Van der Waals vi knh enzym.

    - Nhm kha hot ng (capping group) hay vng nhn din b mt (C): thng l

    cc aryl hoc 1 s vng khc, nm trn b mt enzym.

    Hnh 1.9. Cng thc c in ca HDI v v tr ca HDI trong ti enzym HDAC

    Cu trc tinh th kt tinh ca cc HDAC lin kt vi 1 s cht c ch HDAC

    cho thy phn A, B v 1 phn ca C nm trong ti enzym, lm y khong trng trong

    lng knh enzym. Phn cn li ca C tng tc vi phn vnh trn b mt ming ti

    enzym. Nhm nhn din b mt C c th lin kt vi phn cu ni thng qua 1 s lin

    kt peptid, lm tng kh nng phn cc v gp phn ci thin dc ng hc cho HDIs.

    Vic nghin cu thit k cng thc cho cc HDIs mi u da trn cu trc c in

    ny.

    1.3. TNH HNH NGHIN CU TRN TH GII V CC CHT C CH

    HDAC

    Vic pht hin tc dng lm gim s bit ha t bo trong bnh bch cu Friend

    v c ch chu trnh t bo bnh thng c pha G1 v G2 ca TSA m ra mt

    hng nghin cu trong con ng tm thuc mi iu tr ung th [91]. T nhng nm

    90 ca th k trc, rt nhiu nh khoa hc trn th gii tp trung nghin cu v

    hng trm bi bo c cng b trong qu trnh tm kim cc cht c ch HDAC.

    Cho n nay, bn cnh 2 cht l vorinostat (Zolinza) v depsipeptid (Romidepsin)

    c FDA ph duyt s dng trong iu tr u lympho da t bo T, cn c khong

    hn 10 cht ang c nghin cu pha lm sng I, II (bng 1.2). Vit Nam, vn

    cha c nh khoa hc no quan tm n thit k, tng hp cc cht c ch HDAC

    ngoi cc cng b m nhm nghin cu ca chng ti ang tin hnh.

    C

    A B

    ArNH

    NH

    OH

    n

    OO

    B AC

  • 19

    Bng 1.2. Cc cht c ch HDAC v ang c th lm sng [56]

    Nhm Hp cht Pha lm

    sng

    Loi ung th

    Peptid vng Depsipeptid

    (FK228)

    I, II Tng c, CLL, AML, CTCL, u

    a ty xng, NHL t bo T

    ngoi vi, RAI khng thyroid, ung

    th i trng giai on mun

    Cc benzamid MS-275

    CI-994

    MGCD-0103

    I, II

    I, II

    II

    Tng c, u lympho, AML, u

    hc sc t c tnh di cn giai

    on mun

    Tng c, NSCLC, t bo thn,

    tu

    Tng c, ung th bch cu,

    MDS

    Acid bo mch

    ngn

    Butyrat

    AN-9 (tin thuc)

    Acid valproic

    Phenyl butyrat

    I, II

    I, II

    I, II

    I

    Ung th i trng

    Tng c, NSCLC

    Tng c, ung th mu, AML,

    MDS, CTCL, u trung biu m

    Tng c, AML/MDS

    Acid

    hydroxamic

    SAHA

    PXD101

    NVP-LAQ824

    LBH-589

    ITF-2357

    SB-939

    CRA 024781

    ph duyt

    I, II

    II

    I

    II, III

    II

    I

    I

    I

    CTCL

    Tng c, ung th mu

    Ung th mu

    Tng c, ung th mu

    Tng c, AML, ALL, MDS

    U lympho Hodgkin

    Tng c, ung th mu

    * Ch thch: NSCLC, carcinom t bo phi khng nh; AML, ung th bch cu ty bo cp; MDS, hi chng lon sn ty; CTCL, u lympho da t bo T; ALL, ung th bch cu cp; CLL, ung th bch cu mn.

    1.3.1. Cc peptid vng

    y l nhm cc cht c cu trc phc tp nht trong HDIs, tc dng c ch

    HDAC mnh tng t nh cc acid hydroxamic gm: Depsipeptid (FK-228), apicidin,

    trapoxin A... v cc CHAP (cyclic hydroxamic acid-containing peptide) (hnh 1.10).

    a s cc cht trong nhm ny c tc dng c ch HDAC nng nanomol.

  • 20

    Depsipeptid l polypeptid t nhin c phn lp t nm Chromobacterium violaceum

    v l cht c ch HDAC th 2 c FDA ph duyt trong iu tr u lympho da t bo

    T (thng 11/2009). Cu trc ca depsipeptid kh phc tp vi 4 lin kt peptid.

    Depsipeptid l tin thuc, khi vo c th c kh ha to ra nhm sulfydryl ca

    redFK c tc dng tt vi HDAC nhm I, c bit HDAC1, 2. Nhm -SH ca redFK

    c th phn ng vi cystein tn trong ti enzym to lin kt cng ha tr disulfid. Tnh

    n nh v k nc ca FK228 gip cho n d dng qua c mng t bo, do tc

    dng hiu qu hn cc HDIs khc [45].

    Cc CHAP l sn phm kt hp peptid vng v acid hydroxamic. Trong cu

    trc ca chng, chui acid hydroxamic c gn vi vng peptid thay cho nhm

    epoxyketon trong trapoxin hay cc hp cht t thin nhin khc. Mt s hp cht c

    tng hp bng cch thay i s lng acid amin trong cu trc vng, s khng i

    xng ca cc acid amin v chiu di chui hydroxamic. Trong s , CHAP31 c tc

    dng tt nht (c ch HDAC1 vi IC50 = 3,32 nM), v bn hn TSA trong t bo (t1/2 di hn) [63].

    Hnh 1.10. HDIs c cu trc peptid vng

    1.3.2. Dn cht benzamid

    Dn cht benzamid c tc dng c ch HDAC in vitro v in vivo c cng b

    nm 1999 bi Suzuki v cng s thuc cng ty dc Mitsui [63]. Nhm ny bao gm

    mt s cht MS-275, CI-994, MGCD-103 (hnh 1.11), chng c hot tnh km hn cc

  • 21

    acid hydroxamic v cc peptid vng, c ch HDAC nng micromol [39].

    Hnh 1.11. HDIs l cc benzamid

    MS-275 v CI-994 ang c th nghim lm sng pha 2. MS-275 lm gim

    s acetyl ha qu mc ca histon trong nhiu loi ung th, gim s biu th qu mc

    ca p21WAF1/CIP1 v gelsolin. CI-994 l 4-acetylamino-N-(2-aminophenyl)benzamid,

    c chng minh c tc dng trn t bo ung th ngi v chut. Nghin cu in

    vitro cho thy CI-994 c tc dng thc y s cht t bo theo chng trnh trn cc t

    bo lympho chut. u im ln ca CI-994 l thuc chng phn bo ng ung [32].

    1.3.3. Cc acid bo mch ngn

    Cc acid bo mch ngn nh acid valproic, natri butyrat, phenylbutyrat (hnh

    1.12) c dng trong lm sng t rt lu (acid valproic l thuc iu tr ng kinh)

    Gn y, tc dng c ch HDAC ca chng mi c nghin cu. Acid butyric l sn

    phm t nhin c tng hp trong c th ngi do chuyn ha acid bo v vi khun

    ln men cht x i trng. Nghin cu cc cht c ch HDAC nhm ny i hi s

    cn trng do chng c th iu ha qu trnh biu hin gen theo cc cch v cng tinh

    vi. Thm vo , nhc im ln ca cc cht ny l p ng hn ch trn lm sng do

    thi gian bn thi ngn v nng t c tc dng cao ( mc nng milimol

    so vi TSA l nanomol) [40,71].

    Hnh 1.12. HDIs l cc acid bo mch ngn

  • 22

    1.3.4. Cc dn cht ceton

    Nhm ny bao gm cc trifluoromethyl ceton v -ketoamid vi hot tnh c

    ch HDAC mc nng micromol (hnh 1.13) [28].

    CF3

    HN

    O

    O

    HN

    HN

    O

    O

    O

    Trifluoromethyl ceton HDAC IC50 = 6,7 M

    -cetoamid HDAC IC50 = 340 nM

    Hnh 1.13. HDIs l cc dn cht ceton

    1.3.5. Cc hydroxamat v dn cht

    Acid hydroxamic l nhm cht c ch HDAC c nghin cu rng ri nht,

    vi nng c ch nm trong khong micromol n nanomol.

    Trichostatin A (TSA) l cht u tin c phn lp t Streptomyces

    hygroscopicus vi tc dng chng nm bi Tsuji v cng s nm 1976 (hnh 1.14).

    Mi nm sau , Morioka v cng s cng Yoshida v cng s chng minh tc

    dng rt tt ca TSA trong vic lm gim s bit ha t bo trong bnh bch cu

    Friend v c ch chu trnh t bo bnh thng c pha G1 v G2 [91]. Tuy nhin,

    nghin cu su hn cho thy ch cu trc (R)-TSA c tc dng c ch s pht trin ca

    chu trnh t bo, gim s bit ha v s bin i ca histon trn chut c t bo ung

    th tuyn v FM3A. TSA c tc dng c ch mnh, c hiu vi HDAC (Ki = 3,4nM)

    v th nghim in vivo trn chu trnh pht trin v bit ha t bo khng nh chc chn

    tc dng c ch enzym ny [63]. Nghin cu gn y xc nh TSA ging nh ligand

    ca receptor hot ha sn sinh peroxisome (troglitazon v BRL46593) v ca

    receptor retinoid X (LG268), c th iu ha s biu hin ca gen Drg-1. Do , TSA

    ng vai tr nh cht ngn cn s di cn trong ung th i trng. Vic sn xut TSA

    rt tn km m li khng hiu qu (tri qua 20 bc v hiu sut 2%) nn nghin cu

    tm ra cc cht c ch HDAC thay th TSA v ang c nhiu nh nghin cu

    quan tm. Hin nay, TSA ch yu dng lm cht i chiu trong nghin cu tm ra cc

    cht c ch HDAC mi [71].

    Mt cht c ch HDAC tng hp l acid suberoylanilid hydroxamic (SAHA)

    (hnh 1.14) c nghin cu. Bo co cho thy SAHA c ch s pht trin t bo,

    dn n kt thc s bit ho v ngn nga hnh thnh khi u trn chut. Nm 2006,

    sau khi tri qua cc pha trong tin trnh th nghim lm sng, SAHA (Vorinostat,

    Zolinza) c FDA ph duyt s dng trong iu tr u lympho da t bo T. SAHA

  • 23

    c chng minh nhy cm vi cc dng t bo Hut78, HH, M v nhy cm vi t

    bo lympho mu ngoi vi nguyn pht bnh nhn u lympho da t bo T [92]. SAHA

    lm tng s acetyl ho ca cc histon H2B, H3 v H4, ng thi lm tng s biu th

    ca p21 v Bax trong khi li lm gim s biu th ca STAT6 v lm gim mc

    ca STAT6 phospho. Tt c cc nh hng dn n hot ho caspase 3, s phn

    chia ca PARP v s cht t bo theo chng trnh. Hin nay, Zolinza ang tip tc

    c th nghim lm sng dng phi hp vi cc ho tr liu khc nh tamoxifen,

    bortezomib, temozolomid...

    Bn cnh , nhiu cht c ch HDAC dn cht acid hydroxamic ang c

    nghin cu rng ri v c chia thnh nhiu phn nhm nh: acid hydroxamic mch

    thng, dn cht cinnamic (CBHA, LAQ 824, LBH 589, PXD101), dn cht

    phenyl...(hnh 1.14). c im chung ca nhm ny l nhm chc acid hydroxamic d

    to phc vi ion Zn2+ ca HDAC nn c ch khng chn lc c HDAC nhm I, II v

    b chuyn ha nhanh [58,89].

    Hnh 1.14. HDIs c cu trc hydroxamat

    Nh trn cp n, cc acid hydroxamic c hiu lc c ch HDAC tt

    song chng c nhc im l c ch khng chn lc v na i in vivo ngn. Chnh v

    vy, rt nhiu nhm nghin cu trn th gii ang n lc tm kim cc dn cht mi

    da trn phin mu ca TSA, SAHA v cc cht tm c. Da trn c im cu

    trc ca cc cht c ch HDAC (mc 1.2.3), cc nghin cu c th tin hnh thay i

  • 24

    mt trong 3 phn cu trc: nhm kha hot ng, cu ni hoc nhm chc

    hydroxamic. Sau y l tng kt mt s nghin cu trn th gii v thay i cu trc

    ca cc acid hydroxamic.

    1.3.5.1. Thay i cu ni

    * Cc N-hydroxy-2-propenamid cc acid hydroxamic tng t TSA

    Nhm cc N-hydroxy-2-propenamid (AH1, hnh 1.15) c thit k v tng

    hp da trn c s nghin cu cu trc ca TSA, oxamflatin v MS-275. Nhn chung,

    cc dn cht ny c tc dng c ch HDAC yu hn TSA song mnh hn MS-275 v

    tng t oxamflatin. Cht c IC50 mnh nht l 172 nM [44].

    Hnh 1.15. Cc dn cht N-hydroxy-2-propenamid

    Trong mt nghin cu tng t, cc nh khoa hc ti Trung tm nghin cu

    Sigma-tau, Pomezia () thit k v tng hp mt dy cc acid biphenyl-4-yl-

    acrylohydroxamic (AH2) [19]. nh gi hot tnh ca cc cht tng hp c cho

    thy nhiu cht trong dy c tc dng c ch HDAC2 tng ng vi SAHA. Khi

    ko di cu ni thm mt lin kt i, hot tnh c ch HDAC2 gim ng k (AH3,

    hnh 1.16). Tuy nhin, dn cht kh ha ca 7 li c ch HDAC2 kh mnh vi IC50 =

    0,72 M (AH4, hnh 1.16). ng phn v tr ca AH2b (R l 4-hydroxyphenyl) vn

    duy tr tc dng c ch HDAC2 (AH5, hnh 1.17). Tng t, dn cht AH6 vi mt

    vng phenyl b kh ha cng cho tc dng c ch HDAC2 tng ng (hnh 1.17).

    Tuy nhin, kh ha ng thi c lin kt i mch nhnh lm mt hon ton i lc

    vi HDAC2 (AH7, hnh 1.17).

  • 25

    Hnh 1.16. a) Cc acid biphenyl-4-yl-acrylohydroxamic (AH2); b) Cc dn cht vi

    cu ni c hai lin kt i (AH3) v dng kh ha ca AH3 (AH4)

    Hnh 1.17. Mt s dn cht c lin quan ca AH2b

    * Cc amid ngc ca SAHA

    Nhm nghin cu thuc cng ty TopoTarget (Anh) thit k v tng hp gn

    40 dn cht amid ngc (AH8) ca SAHA (hnh 1.18) [6]. Nhiu cht trong s ny c

    hot tnh c ch HDAC tng ng, thm ch mnh hn SAHA. Trong , hai cht

    c th nghim m hnh ung th in vivo trn chut v cho kt qu rt kh quan,

    nh hng cho cc nghin cu tip theo. Lin quan cu trc - tc dng rt ra c t

    cc dy cht ny cho thy nhng c im tng t SAHA, l: i) nhm acid

    hydroxamic l cn thit cho hot tnh c ch HDAC mnh; ii) cu ni 5-6 C l ti u;

  • 26

    iii) lin kt amid c vai tr trong tng tc vi trung tm hot ng song c th thay

    i; iv) phn Ar l nhn thm cho hot tnh mnh hn, nu c cu ni gia nhn thm

    vi nhm amid th cu ni khng no tt hn [6].

    Hnh 1.18. Cc dn cht amid ngc ca SAHA

    * Cc aryloxyalkanoic N-hydroxyamid: dn cht ca SAHA khng c nhm amid

    Nhm amid ni gia mch alkyl v nhn phenyl ca SAHA c cho l cn

    thit song c th thay th. Chnh v vy, y l v tr c nhiu nghin cu quan tm

    kho st thay th bng nhng phn cu trc hoc nhm chc khc nhau. Mt trong

    nhng nghin cu u tin c cng b l thay nhm amid bng oxy (-O-) to ra cc

    aryloxyalkanoic N-hydroxyamid (AH9) (hnh 1.19) [58].

    Hnh 1.19. Cc aryloxyalkanoic N-hydroxyamid (AH9)

    Kt qu th hot tnh in vitro cho thy dn cht AH9a c mt nhm th n

    gin nh N,N-dimethylamino (thch hp cho vng kha hot ng ca TSA) c th

    mang li hiu lc c ch tt. Tuy nhin, m rng vng s nc ca nhm kha hot

    ng c th lm tng hot tnh ln nhiu; iu ny c th ci thin bng vic dng

    nhm 4-clorophenyl nh trong AH9b, hoc bng s hp nht vng nh trong AH9p

    v AH9q. Cc vng phng ca AH9p v AH9q gp phn to nn hiu lc, c v nh

    do s u tin chim gi phn s nc v cu trc phng tng ng ca vng kha hot

    ng ca cc enzym [58].

    Nh vy, cc aryloxyalkanoic hydroxyamid nu trn l mt vi cht c ch

    HDAC c hiu qu nht c bit lin quan n tnh n gin v cu trc. Hiu lc

    ca cc aryloxyalkanoic hydroxyamid cho thy nhm carbonyl (nh c mt trong

  • 27

    trichostatin A v SAHA) ln mt cu ni rn chc u khng cn thit thu c tc

    dng c ch HDAC mc nng nanomol. Cc cht c cu trc aryloxy ny chng

    t s n nh in vivo tt hn khi so snh vi cc cht c ch HDAC cu trc amid.

    Thm vo , cht AH9q c ch s tng sinh ca HeLa (IC50 = 7 M) v dng t bo

    MCF-7 (IC50 = 5 M) [58].

    * Cc dn cht -alkoxy ca SAHA

    Phn tch cu to trung tm hot ng dng ti ca HDAC, nhm nghin cu

    thuc trung tm nghin cu Sigma-Tau (Pomezia, ) [37] c bit ch phn ming

    ti vi cc vng acid amin c th tham gia nhiu tng tc quan trng vi nhm nhn

    din b mt hoc cc nhm ln cn. Hai hp cht thin nhin amamistatin A v B vi

    cu trc cha nhm N-formyl-N-hydroxylysin c bo co c tc dng c ch

    HDAC ng k (hnh 1.20).

    Hnh 1.20. Cu trc ca amamistatin A, B [37]

    Da trn c s ny, nhm nghin cu thit k v tng hp dy dn cht -

    alkoxy ca SAHA (hnh 1.21).

    Hnh 1.21. Cc dn cht -alkoxy ca SAHA

    Kt qu sng lc hot tnh c ch HDAC2 cho thy tt c cc dn cht -

    alkoxy (dng racemic) ca SAHA u cho gi tr IC50 mc rt thp (0,05-0,5 M),

    nhiu cht tc dng tng ng SAHA. c bit, c tnh i vi t bo ung th ca

    cc dn cht -benzyloxy th hin mnh hn r rt so vi SAHA trn c 3 dng t bo

  • 28

    NB4 (ung th bch cu tin ty bo cp), H460 (ung th phi ngi), HCT-116 (ung

    th i trng). Kt qu ny cho thy cc nhm th -alkoxy c hiu qu tng cng

    tc dng sinh hc cho cc dn cht ny, c th do chng to thm cc tng tc vi

    cc aminoacid thuc vng mp ti ti trung tm hot ng ca enzym. ng ch l

    cu hnh ca nhm chc -alkoxy khng nh hng n hot tnh sinh hc, th hin

    qua tc dng ca dn cht p-methoxybenzyl ether AH10 (racemic) (hnh 1.22), AH10

    (dng R) v AH10 (dng S). y l im ht sc c ngha i vi tng hp cc dn

    cht ny v vn tch cc ng phn s khng cn t ra.

    Hnh 1.22. Cu trc ca dn cht p-methoxybenzyl ether (AH10) [37]

    Bng 1.3. Tc dng c ch HDAC2 v c tnh t bo ca dn cht -alkoxy (AH10)

    Cht HDAC2 (IC50 M) IC50 (M)

    0,05 NB4 H460 HCT-116

    SAHA + 0,70 3,40 1,20

    AH10 + 0,12 0,52 0,22

    AH10 + 0,11 0,45 0,25

    AH10 + 0,07 0,50 0,39

    Tng phn vi cc dn cht -alkoxy trn, cc dn cht -alkyl ca SAHA

    li hu nh khng c tc dng c ch HDAC (hnh 1.23) [12]. Nh vy, c th thy

    vng lin kt vi Zn2+ ca HDAC l tng i nh v khng chp nhn cc nhm th

    cng knh. Mi thay i v cu trc vng ln cn vi nhm acid hydroxamic cn

    ch im ny.

  • 29

    Hnh 1.23. Mt s dn cht -alkyl ca SAHA

    1.3.5.2. Thay i nhm kha hot ng

    * Cc acid phenylthiazol-hydroxamic tng t SAHA

    Bn cnh cc nghin cu thay i phn cu ni, hng nghin cu kho st

    thay i phn nhm kha hot ng (nhm nhn din b mt, SRG) cng c rt

    nhiu nh khoa hc quan tm. Cc nh khoa hc thuc Vin nghin cu qun i

    Walter Reed (M) thit k v tng hp hng trm dn cht acid hydroxamic mang

    hp phn phenylthiazol thay th vo v tr ca phenyl trong SAHA (AH11, hnh 1.24)

    [23]. Mt dn cht oxazol l WR301849 cng c tng hp [52].

    Hnh 1.24. Cc acid phenylthiazol hydroxamic tng t SAHA

    Kt qu nh gi tc dng trn HDAC cho thy dn cht WR301801 (AH11a)

    vi nhm kha hot ng l 3-aminophenyl-5-thiazolyl c tc dng c ch mnh nht

    vi IC50 = 10,4 nM, mnh hn c SAHA trn cng th nghim. ng phn v tr ca

    WR301801 l WR301826 (AH11b) (nhm th amino v tr ortho) cng c tc dng

    mnh tng ng SAHA [23].

    S dng hai cht WR301801 v WR301826 lm nhng cht dn ng mi,

    nhm nghin cu ca Alan P. Kozikowski thuc i hc Illinois (Chicago, M) tip

    tc thit k dy acid phenylthiazol-hydroxamic dn cht ha da trn nhm amino ca

    vng phenyl (hnh 1.25) [51]. Kt qu cho thy, khi nhm amin th trn vng phenyl

    c acyl ha bng nhng nhm cng knh, tc dng c ch nhiu tp HDAC tng.

    Tc dng mnh nht thu c vi dn cht AH11a-5 (hnh 1.25). IC50 ca dn cht

    ny vi HDAC2, HDAC3 thp di mc 0,2 nM. Kt qu th c tnh trn 5 dng t

  • 30

    bo ung th ty cng b vi AH11a, AH11b, AH11a-2 cho thy cc dn cht ny u

    c IC50 nh hn 3 M [51].

    Hnh 1.25. Mt s acid phenylthiazol hydroxamic

    * Cc acid biphenyl-hydroxamic tng t SAHA

    Trong qu trnh nghin cu cc dn cht acid phenylthiazol-hydroxamic, nhm

    nghin cu ca Alan P. Kozikowski cng ng thi tin hnh thit k v tng hp mt

    dy cc dn cht acid biphenyl-hydroxamic tng t SAHA (hnh 1.26) [51]. Kt qu

    cc dn cht biphenyl c ch HDAC mnh hn SAHA trn 6 loi HDAC (HDAC1, 2,

    3, 8, 10, 6). Khi gn thm nhm -NH2 vo v tr ortho trn vng phenyl th 2 hot tnh

    gim song khi nhm -NH2 ny c acyl ha bng nhng nhm aminoacyl cng knh,

    tc dng c ch HDAC li c tng cng. iu ny chng t phn nhn din b mt

    ca trung tm hot ng ca HDAC c th chp nhn nhiu nhm c kch thc ln.

    Kt qu ny cng gi cc tng tc c to lp thm t nhng nhm aminoacyl ny

    vi cc acid amin ti vnh ca ti hot ng lm tng i lc i vi HDAC ca cc

    dn cht. Mt s acid biphenyl-hydroxamic cng cho c tnh trn 5 dng t bo ung

    th ty th nghim nhng tc dng khng tt bng cc acid phenylthiazol hydroxamic.

    Hnh 1.26. Cc dn cht acid biphenyl-hydroxamic

    * Cc acid isoxazol-hydroxamic tng t SAHA

    Trong qu trnh nghin cu cc dn cht acid phenylthiazol-hydroxamic, nhm

    nghin cu ca Alan P. Kozikowski thuc i hc Illinois (Chicago, M) tng hp

    dn cht acid phenylisoxazol-hydroxamic WR301849 (hnh 1.24) [52]. Dn cht

    isoxazol ny c tc dng c ch cc HDAC1, 3 v 6 rt mnh vi IC50 thp n 0,002

    nM. Tip tc mch nghin cu ny, mt s dn cht trong vng isoxazol c a

  • 31

    vo v tr ngay st cnh nhm acid hydroxamic c thit k v tng hp (hnh

    1.27) [79].

    Hnh 1.27. Cc acid isoxazol-hydroxamic

    Kt qu th hot tnh c ch HDAC cho thy mt s dn cht trong cc acid

    isoxazol-hydroxamic tng hp c ch c 5 tp HDAC1, 2, 3, 6 v 10 vi IC50 trung

    bnh khong 150 nM [79]. Tc dng ny km hn nhiu so vi cc acid phenylthiazol-

    hydroxamic AH11 v acid biphenyl-hydroxamic AH12. C th nhn xt, khi c mt

    vng isoxazol cnh nhm hydroxamic, nhm kha hot ng l quinolin hoc

    biphenyl khng ti u cho hot tnh, trong khi hai dn cht vi vng 5-phenylthiazol

    (AH13a, AH13b) c tc dng c ch HDAC kh mnh, gn tng ng SAHA

    (hnh 1.27). y cng l hai dn cht th hin c tnh t bo mnh nht vi IC50 thp

    n 1 M. iu ngc nhin l mc d AH13b c ch HDAC mnh hn AH13a song

    AH13a li c c tnh t bo mnh hn AH13b [79]. C th s c mt ca nhm 3-

    amino AH13b lm gim tnh thm t bo ca cht ny, dn n c tnh t bo

    thp hn so vi AH13a. C th cc dn cht acyl ha ca AH13b s ci thin c tc

    dng trn HDAC v t bo, tng t nh vi cc dn cht acid phenylthiazol-

    hydroxamic AH11.

    * Cc dn cht acid thiophen-2-hydroxamic

    Mt trong nhng nghin cu ng ch cng b gn y l cc dn cht acid

    thiophen-2-hydroxamic ca cng ty Argenta Ltd. (Anh) [67]. Bng phng php sng

    lc o da trn cu trc tinh th ca HDLP (HDAC-like protein) (PDB: 1C3R), tin

    hnh vi 644 acid hydroxamic sn c, nhm nghin cu la chn c 98 ng vin

    tng hp v th tc dng c ch HDAC. Kt qu tm c cht dn ng vi

    cu trc hon ton mi ADS100380 (hnh 1.28). ADS100380 c ch HDAC vi IC50 =

    0,75 M v c tnh trn t bo MCF7 vi IC50 = 11,40 M. Docking ADS100380 vo

    trung tm hot ng ca HDAC cho thy phn hydroxamic ca cht ny trng kht vi

  • 32

    phn hydroxamic ca SAHA cn cu trc thiophen nm dc theo ng cu ni thn

    du ca SAHA ti trung tm hot ng ca HDAC [67].

    SN

    N

    F3C

    H3CNHOH

    O

    Hnh 1.28. ADS100380

    Nhm tm kim cc dn cht vi hot tnh mnh hn, nhm nghin cu tin

    hnh thit k dy cc dn cht acid 5-(1H-pyrazol-3-yl)-thiophen-2-hydroxamic. Kt

    qu thu c cht ADS102550 c hot tnh tt hn cht dn ng, c ch HDAC vi

    IC50 = 0,029 M, c tnh trn MCF-7 vi IC50 = 0,30 M. ADS102550 c t1/2 = 2,5

    gi (tim tnh mch), di gp ba ln ca SAHA (0,7 gi). Khi dng ng ung, c

    SAHA v ADS102550 u c sinh kh dng km. Tuy nhin, khi tim vo mng

    bng, ADS102550 c sinh kh dng cao. Tip tc nh gi tc dng chng ung th in

    vivo s dng m hnh chut tri lng (nude mice) mang t bo ung th ngi

    HCT116, kt qu cho thy ADS102550 c ch 33% s pht trin ca khi u. Tuy

    nhin, ng tic l ADS102550 cn c ch cytochrom P450 kh mnh vi IC50 = 0,51

    M [67].

    Nhm tm kim cc dn cht mi ci thin c nhc im ca ADS102550,

    nhm nghin cu ti Argenta tip tc thit k, thay i cu trc theo cc hng i) thay

    i vng pyrazol bng cc vng khc nhau, sau ii) kho st cc nhm th v cu ni

    trn vng mi (hnh 1.29).

    Hnh 1.29. Cc nh hng ti u ha cu trc ca ADS102550

    Theo hng th nht, nhm nghin cu tin hnh tng hp cc dn cht

    trong pyrazol c thay bng cc nhm imidazol, thiophen, phenyl, 2-pyridyl, 3-

    pyridyl, 4-pyridyl v pyrimidyl. Cc cht c sng lc hot tnh c ch HDAC v s

  • 33

    b nh gi c tnh t bo trn dng t bo ung th v MCF7. Kt qu sng lc dy

    ny cho thy dn cht AH14c (mang vng 2-pyridin) v AH14f (mang vng

    pyrimidin) c hot tnh mnh nht trn HDAC v t bo MCF7 (hnh 1.30) [67].

    Hnh 1.30. Cc arylthiophen hydroxamat

    T kt qu dy dn cht arylthiophen hydroxamat, nhm nghin cu la

    chn AH14c lm nhng cht dn ng mi v kho st cc nhm th gn trn vng

    2-pyridin. Hn 50 dn cht khc nhau c thit k, tng hp (hnh 1.31) [67].

    Hnh 1.31. Cc acid pyridin-thiophen-hydroxamic

    Tc dng sinh hc ca dy dn cht AH14ca AH14cm cho thy: i) Nhm th

    trn vng pyridin v tr 5 tt hn v tr 6; ii) Khong cch gia nhm phenyl mch

    nhnh v vng pyridin c th dao ng t 2-5 nguyn t m vn cho tc dng tt; iii)

    C th chn thm O hoc N vo mch nhnh m vn gi c tc dng. T dy dn

    cht ban u ny, nhm nghin cu ti Argenta Ltd. chn AH14cb (ADS102770)

    nghin cu su hn. ADS102770 c tc dng mnh hn SAHA trn c HDAC v t

    bo. ADS102770 cng mnh hn hai ln so vi ADS102550 trn HDAC v 3-6 ln

    trn t bo (MCF7 v MDA-MB231). Tc dng c ch cytochrom P450 ca

    ADS102770 gim 10 ln so vi ADS102550. Khi th nghim vi t bo gan ca chut

    cng, ADS102770 bn hn ADS102550 v SAHA. Tuy nhin, n nh ca

    ADS102770 li km hn so vi ADS102550 khi th vi microsom ca chut nht

    (tim tnh mch, t1/2 = 0,17 gi so vi 2,5 gi ca ADS102550 v 0,8 gi ca SAHA).

    B li, ADS102770 c sinh kh dng ng ung tng i cao hn so vi SAHA v

    ADS102550 khi th nghim trn chut cng (AUC, 3,3 g h/mL so vi 0,4 g h/mL

    ca SAHA v 0,1 g h/mL ca ADS102550) [67].

  • 34

    1.3.5.3. Thay i nhm chc hydroxamic

    * Cc dn cht sulfonamid

    Gn y, cc nh khoa hc ti Trung tm nghin cu ca MethylGene (Canada)

    cng b cc dn cht sulfamid trong nhm chc sulfonamid c kho st thay th

    cho phn acid hydroxamic. Trong dy dn cht u tin vi nhm nhn din b mt l

    biphenyl, hu nh khng dn cht no c kh nng c ch HDAC, IC50 trn HDAC1

    v HDAC6 u > 10 M (hnh 1.32).

    Hnh 1.32. Cc dn cht biphenyl sulfamid

    Ch khi thay nhm biphenyl bng mt s nhm nhn din b mt khc nh

    phenyl, quinolin, 5-phenylthiazol, tc dng c ch HDAC6 mc va phi (IC50,

    0,39-1,50 M) mi c ghi nhn (AH16, hnh 1.33). ng ch nht l hai dn cht

    trong phn cu ni 6-aminohexanoyl c thay bng cu ni lysyl (AH17, hnh

    1.33), c tc dng c ch c HDAC1 v HDAC6 vi gi tr IC50 mc di 1 M

    [87]. T kt qu ny, mt dy cc dn cht sulfamid khc vi cu ni lysyl v phn Ar

    l nhm 5-phenylthiazol c thit k, tng hp (AH18, hnh 1.33) [54]. Nhn

    chung, hu ht cc dn cht u c tc dng c ch c 2 loi HDAC1 v 6 vi IC50 < 1

    M. C th nhm -amin ca phn lysin c tng tc vi cc aminoacid phn ming

    ti ca trung tm hot ng ca HDAC.

    Hnh 1.33. Mt s dn cht sulfamid khc [54]

  • 35

    Mt kt qu ng ngc nhin khc l cc dn cht sulfamid ny, cu ni amid

    c v khng ng vai tr quan trng i vi hot tnh c ch HDAC. Kt qu ny th

    hin mt dy cc dn cht AH19 khng mang cu ni amid (hnh 1.34) nhng hot

    tnh c ch HDAC1 v 6 vn rt tt (HDAC1, IC50 t 0,1-4,9 M; HDAC6, IC50 t

    0,1-1,8 M) [54].

    Hnh 1.34. Cc dn cht sulfamid khng mang cu ni amid

    Cc kt qu trn cho thy nhm sulfamid hon ton c trin vng thay th cho

    nhm acid hydroxamic trong tng tc vi Zn2+. Xt v mt chuyn ha, nhm

    sulfamid c th bn hn in vivo so vi nhm chc acid hydroxamic.

    * Cc dn cht thiocarbonat, dithiocarbonat v trithiocarbonat

    Cng trong n lc tm kim cc cht c ch HDAC khng phi acid

    hydroxamic, cng ty Nycomed GmbH (c) thit k, tng hp v nh gi hot

    tnh ca hng lot dn cht thiocarbonat, dithiocarbonat v trithiocarbonat. Kt qu

    dn cht trithiocarbonat c trin vng hn c khi cn nhc c hai kha cnh l tc dng

    c ch HDAC v tc dng c ch s pht trin ca t bo (hnh 1.35) [20].

    Hnh 1.35. Mt s dn cht trithiocarbonat

    Nghin cu su hn v dy trithiocarbonat thu c mt s dn cht c ch

    HDAC tim nng vi gi tr IC50 mc thp n di M (hnh 1.36) [20]. Cht

    AH21a (R = 4-AcNH, Z = S) cho tc dng c ch HDAC (IC50 = 0,857 M) v c

    tnh trn t bo Hela (IC50 = 1,46 M) tt nht trong dy AH21. Vi dy cht AH22,

    cht AH22g (RRN l 4-methoxy benzylamin) c IC50 trn HDAC l 0,600 M, c

    tnh trn t bo Hela l 1,45 M [20]. Nu so snh vi SAHA th nhn chung cc dn

    cht trithiocarbonat mnh nht vn km SAHA khong 100 ln. Tuy nhin, xt v kha

    cnh dc ng hc, cc trithiocarbonat c trin vng tt hn in vivo.

  • 36

    Hnh 1.36. Mt s trithiocarbonat khc v cht tng t

    * Cc dn cht thiol v mercaptoceton

    Tip tc hng nghin cu tm kim cc cht c ch HDAC khng phi acid

    hydroxamic, nhm nghin cu ti cng ty Daiichi Pure Chemicals ca Nht thit

    k, tng hp (hnh 1.37) v cng b tc dng c ch HDAC ca mt dy cc thiol y

    trin vng [78]. Bt u bng vic thay th nhm -CONHOH bng -SH, nhm nghin

    cu thu c hp cht AH23a (Ar = Phenyl; X = NHCO; n = 4) vi tc dng c ch

    HDAC IC50 = 0,21 M. Tip tc ti u ha cu trc ny, nhm nghin cu thu

    c cc dn cht trong nhm nhn din b mt Ph c th thay th bng cc nhm

    3-PhPh, 3-quinolyl, 2-naphthyl v 2-benzofuranyl to ra nhng cht c ch HDAC

    mi vi hot lc tng t SAHA nh cht AH23i (Ar = 3-PhPh; X = NHCO; n = 4),

    AH23s (Ar = 2-benzofuranyl; X= CONH; n = 4) [78].

    Hnh 1.37. Cc dn cht thiol

    Gn y, nhm nghin cu thuc cng ty Kalypsys (M) sng lc mt th

    vin ha cht vi hn 600 000 cht. Kt qu tm c cht dn ng disulfid (hnh

    1.38). Tuy nhin, thc cht disulfid ny khng phi l cht c hot tnh m trong iu

    kin th nghim, cht disulfid nhanh chng b kh ha thnh dn cht -

    mercaptoceton (-MRC) mi l dng hot ng. -MRC c ch HDAC vi IC50 =

    0,135 M, tng ng vi nhiu dn cht acid hydroxamic [38]. N lc ti u ha

    cu trc da trn -MRC dn ti ng vin lm sng KD5170 (hnh 1.38). KD5170

    th hin hot tnh c ch HDAC vi IC50 = 0,045 M, mnh hn c SAHA. Ngoi ra,

    KD5170 cn c ch s acetyl ha -tubulin, mt mc tiu phn t khc ca thuc iu

    tr ung th. Trn 60 dng t bo th nghim chun ca Vin nghin cu ung th M

    (NCI), KD5170 th hin c tnh vi EC50 = 0,1-7,7 M. Cc t bo ung th mu c

    bit nhy cm hn vi KD5170 (EC50 0,5 M). Trn m hnh chut mang t bo ung

    th i trng ngi (dng HCT-116), liu 42 mg/kg x ngy, KD5170 c ch s pht

    trin ca khi u ti 56% so vi nhm trng [38].

  • 37

    NH

    O

    S

    S

    O O

    O

    N

    KD5170

    O

    SS

    O

    O

    Br

    BrDisulfid

    SH

    O

    Br-MRC

    Hnh 1.38. T disulfid n KD5170

    Nghin cu chuyn ha in vivo cho thy KD5170 thc cht vn l tin thuc.

    Khi vo trong c th KD5170 nhanh chng b thy phn thnh dn cht chuyn ha

    dng -mercaptoceton. Chnh dng -mercaptoceton ny to chelat vi Zn2+ (hnh

    1.39) [38].

    NH

    O

    S

    S

    O O

    O

    N

    KD5170

    O

    NH

    O

    SH

    S

    O O

    O

    N

    NH

    O

    SH

    S

    O O

    O

    N

    Zn

    NH

    O

    SH

    S

    O O

    O

    N

    Zn

    hoc

    Hnh 1.39. S thy phn v to chelat vi Zn2+ ca KD5170

    Nh vy, nghin cu thay th nhm chc hydroxamic gn ion Zn+ bng cc

    nhm khc nh thiol, sulfamid, -mercaptoceton ang c nhiu nh khoa hc

    quan tm vi hy vng tm ra cht c ch chn lc tp HDAC khc nhau, vi mc tiu

    chn lc trong iu tr ung th.

  • 38

    Tm hiu v cc cht c ch HDAC c bit n v tnh hnh nghin cu

    trn th gii trong nhng nm gn y v cc cht c ch HDAC, c th rt ra mt s

    nhn xt sau:

    - Cu trc ca cc cht c ch HDAC rt a dng, chng t cu trc trung tm

    hot ng dng ti ca HDAC rt linh ng, c th bin i ph hp vi cu trc

    rt khc nhau ca c cht.

    - Cc peptid vng tc dng c ch HDAC mnh mc nng nanomol. Tuy

    nhin cu trc ca chng rt phc tp nn kh khn cho qu trnh tng hp cng nh

    khng th thu c hiu sut cao. Mt i din trong nhm ny l depsipeptid c

    FDA ph duyt trong iu tr u lympho da t bo T nm 2009. Nhng tc dng ca

    depsipeptid rt hn ch i vi cc loi ung th tng c.

    - Cc dn cht benzamid c cu trc n gin hn nhiu so vi peptid vng.

    Nhng hot tnh km cc acid hydroxamic v peptid vng. Mt s dn cht benzamid

    c th lm sng pha II vi liu php n tr liu. Tuy nhin, kt qu th nghim

    cho thy p ng lm sng rt hn ch.

    - Cc acid bo mch ngn v ceton i in t c u im l cu trc n gin,

    d tng hp. Tuy nhin, hot tnh c ch HDAC yu, p ng hn ch trn lm sng.

    - Cc acid hydroxamic l nhm cht c ch HDAC c nghin cu rng ri

    nht do hot tnh c ch HDAC mnh, cu trc n gin. Tuy nhin, do d to phc

    vi ion Zn2+ nn cc acid hydroxamic c ch HDAC khng chn lc v thi gian bn

    thi in vivo ngn. Mt cht trong nhm ny l SAHA thu c thnh cng ng k

    nht trong iu tr, c FDA ph duyt trong iu tr u lympho da t bo T nm

    2006. Nhng i vi ung th tng c, kt qu th nghim lm sng cho thy SAHA

    rt t hoc khng c hiu qu khi s dng n tr liu. Nh vy, thay i cu trc

    SAHA thu c cht c thi gian bn thi di hn, c hiu qu trn ung th tng

    c l hng nghin cu rt ng ch .

    Nh trnh by mc 1.3.5, cc nghin cu v cc acid hydroxamic hng c

    ch HDAC hin nay tp trung thay i mt trong ba phn cu trc sau: thay i nhm

    kha hot ng, thay i di v bn cht cu ni, thay i nhm chc acid

    hydroxamic u vi mc ch thu c cht c hot tnh c ch HDAC tt hn ng

    thi mong mun tm kim c ng vin cho th lm sng. V thay i phn cu ni,

    kt qu tng hp cc nghin cu (mc 1.3.5.1) cho thy rt nhiu nghin cu c

    tin hnh vi vic a thm d t nh O, gn thm vng hoc nhm th vo cu ni

    tng tng tc ca cu ni vi knh enzym. Do , lun n cng thit k cc dn

    cht acid hydroxamic c nhm kha hot ng l nhn phenyl c gn cc nhm th

  • 39

    khc nhau, a thm lin kt amid vo cu ni vi hy vng tng tng tc vi knh

    enzym. Thay i tip theo l nhm kha hot ng. Rt nhiu bi bo thay i nhn

    phenyl ca SAHA bng cc hp phn khc c cng b, nhng cha c nhm

    nghin cu no s dng khung benzothiazol. Da trn cc cng b v tc dng khng

    ung th ca dn cht benzothiazol, hp phn benzothiazol c la chn thay cho

    nhn phenyl ca SAHA. Mc ch l tng tng tc ca nhm kha hot ng vi

    vng acid amin ming knh enzym. Nh tng hot tnh c ch HDAC v c ch

    s pht trin t bo in vitro, in vivo.

    Tm li, tng hp tnh hnh nghin cu trn th gii v cc cht c ch HDAC

    cho thy hng nghin cu ca lun n ph hp vi xu th nghin cu ca th gii v

    nh hng thit k cc dn cht acid hydroxamic u l cht mi, cha thy cng b

    trong ti liu no.

    1.4. CC PHNG PHP TO LIN KT AMID V TNG HP ACID

    HYDROXAMIC

    Cc cht tng hp trong lun n u c quy trnh tng hp tri qua 2 bc phn

    ng tr ln. Phn ng chnh tng hp cc cht ny u l phn ng to lin kt

    amid. Bc cui cng l phn ng to acid hydroxamic. Qua tham kho ti liu, c

    nhiu phng php to lin kt amid cng nh tng hp acid hydroxamic. la

    chn c phng php ph hp, sau y l tng kt mt s phng php to lin kt

    amid v tng hp acid hydroxamic.

    1.4.1. Cc phng php to lin kt amid

    Lin kt amid c to thnh khi cho mt acid phn ng vi mt amin. Phn

    ng trc tin l to dng mui bn, sau lin kt amid c to thnh khi thng

    c nhit ng hc phn ng th hin trong s 1.1. Phn ng trc tip ny thng

    din ra nhit cao 160 180oC [10,64]. Nhit ny thng khng thch hp cho

    phn ng tng hp cc cht c mt mt s nhm chc khc v tng hp peptid. ng

    thi, phn ng trc tip ny cn gp phi mt s nhc im nh hiu sut thp, s

    racemic ha, kh tinh ch

    S 1.1. Phn ng to lin kt amid trc tip

  • 40

    V vy, hot ha nhm chc acid bng cch gn nhm d tch loi vo carbon

    acyl ca acid trc khi nhm amin tn cng to lin kt amid l cn thit (s

    1.2) [64].

    S 1.2. Phn ng to lin kt amid thng qua acid hot ha

    C nhiu cch hot ha acid carboxylic nh to acyl halid, acyl azid,

    acylimidazol, anhydrid, ester bng cch s dng cc tc nhn hot ha khc nhau.

    Cho n nay, nhiu loi tc nhn hot ha c bit n v c s dng thng

    thng vi mc ch nng cao hiu sut, gim to thnh cc sn phm ph, tng tnh

    chn lc cng nh d tinh ch sn phm. Sau y l mt s phng php to lin kt

    amid thng qua acid hot ha.

    1.4.1.1. Acyl halid

    Cc acyl halid l acyl clorid, acyl fluorid v acyl bromid, trong hay s dng

    nht l acyl clorid (cn c gi l acid clorid). y l mt trong nhng phng php

    u tin hot ha acid v c rt nhiu acyl clorid khc nhau c bn trn th

    thng. Cc tc nhn hay c s dng to acyl clorid l thionyl clorid (SOCl2),

    oxalyl clorid (COCl)2, PCl3, POCl3, PCl5. Sau , lin kt amid c to thnh bng

    cch cho acyl clorid phn ng vi amin (s 1.3). Trong phn ng ny, s c mt

    ca mt base l cn thit phn ng vi HCl to thnh, trnh chuyn nhm amin

    thnh mui HCl khng hot ng [42,64].

    S 1.3. a) Phn ng to acyl clorid; b) Tng hp amid

  • 41

    Cc base hay dng l amin bc 3 nh triethylamin (NEt3), iPr2Net, N-methyl

    morpholin hay pyridin (s 1.4).

    S 1.4. Vai tr xc tc ca pyridin

    1.4.1.2. Acyl azid

    Phng php tng hp amid theo con ng to acyl azid l phng php u

    tin to lin kt peptid bi Curtius t nm 1902 [64]. Acyl azid c th c to

    thnh t dn cht methyl ester, qua 2 bc phn ng. Nhm methoxy c thay th

    bi hydrazin to acyl hydrazid, sau tc dng vi acid nitr thu c acyl azid

    (s 1.5).

    S 1.5. Tng hp amid thng qua to acyl azid

    1.4.1.3. Acylimidazol

    Cc tc nhn hot ha l imidazolium t ra kh hiu qu trong vic to lin kt

    amid. Carbonyl diimidazol (CDI) l cht hay c s dng nht trong nhm ny. C

    ch phn ng th hin trong s 1.6. Imidazol c to thnh ngay trong phn ng

    nn thng khng cn thm mt base khc. Bn cnh , vi cc bc hot ha tng

    t CDI, N,N-carbonylbis(3-methylimidazolium) triflat (CBMIT) cng rt hiu qu

    trong vai tr to tc nhn hot ha tng hp peptid [42,64].

  • 42

    S 1.6. Tng hp amid s dng tc nhn hot ha CDI

    1.4.1.4. Anhydrid

    Mt trong nhng phng php hay c dng hot ha acid carboxylic l

    to anhydrid. Tc nhn acyl to thnh ny hot ng tng i mnh. Cc anhydrid

    ny a s khng sn c, c iu ch ngay khi s dng. C rt nhiu tc nhn hot

    ha to anhydrid nh dicyclohexyl carbodiimid (DCC), diisopropyl carbodiimid

    (DIC), 1-ethyl-3-(3-dimethylamino)carbodiimid.HCl (EDC), ethyl cloroformat,

    isobutyl cloroformat [36,42,64] Trong , hay c s dng nht l cc carbodimid

    (s 1.7). Tuy nhin, nhc im ca phn ng s dng tc nhn hot ha

    carbodiimid l ch mt na lng acid tham gia phn ng to lin kt amid. iu ny

    s gy lng ph v tn km nu acid gi thnh cao.

  • 43

    S 1.7. Tng hp amid s dng tc nhn hot ha DCC

    S dng tc nhn hot ha ethyl cloroformat, isobutyl cloroformat to

    anhydrid hn tp s khc phc c nhc im ca cc carbodiimid nu trn (s

    1.8).

    S 1.8. Tng hp amid s dng tc nhn hot ha ethyl cloroformat

    1.4.1.5. Ester

    Mt phng php hot ha acid carboxylic to tc nhn acyl ha hot ng

    trung bnh l to ester. y cng l phng php to acid hot ha kh ph bin. Vic

    la chn alcol to ester ty thuc vo mc ch ca ngi s dng. V d, trong

    tng hp peptid, alcol hay c s dng nht l benzotriazol hydroxy (HOBt), p-

    nitrophenol (PNP), pentafluorophenol (PFP) (hnh 1.40) [36,42,64]. Bn cnh , cn

  • 44

    c mt s alcol khc c s dng vi cc u im ring nh N-hydroxysuccinimid

    (HOSu) tan trong nc nn d dng loi b giai on tinh ch, hydroxy-7-

    azabenzotriazol (HOAt) hiu qu hn HOBt trong mt s trng hp base amin yu.

    Hnh 1.40. a) Tng hp amid thng qua to ester hot ha; b) Mt s alcol hay dng

    Gn y, mt phng php thng dng trong tng hp peptid l to ester hot

    ha trung gian ngay trong phn ng. Tc nhn hot ha l cc mui uronium,

    phosphonium v immonium ca HOBt, HOAtTc nhn u tin c cng b v

    a vo s dng l benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium

    hexafluorophosphat (BOP) (s 1.9) [64]. Sau , mt lot cc mui uronium v

    immonium cng c bit n vi vai tr tc nhn hot ha nh O-(1H-benzotriazol-

    1-yl)-N,N,NN-tetramethyluronium hexafluorophosphat (HBTU), HATU, N-(1H-

    benzotriazol-1-ylmethylen)-N-methylmethanaminium hexacloro antimonat (BOMI),

    BDMP [36,64].

    S 1.9. Tng hp amid s dng tc nhn BOP [64]

  • 45

    1.4.2. Cc phng php tng hp acid hydroxamic

    Acid hydroxamic l sn phm ca phn ng gia dn cht ca acid carboxylic

    v hydroxylamin. Dn cht ca acid carboxylic c th l ester, acid clorid, anhydrid

    Cho n nay, nhiu phng php tng hp acid hydroxamic s dng cc xc tc khc

    nhau c cng b [7,68,69]. Sau y l tng kt mt s phng php hay dng

    tng hp cc acid hydroxamic hng c ch HDAC.

    1.4.2.1. Tng hp acid hydroxamic t ester

    y l phng php c nhiu nhm nghin cu ng dng tng hp cc

    acid hydroxamic. Hanessian v cng s [37], Andrianov v cng s [6], Marson v

    cng s [58], Belvedere v cng s [8] u tng hp cc acid hydroxamic t dn cht

    methyl ester bng cch cho phn ng vi dung dch hydroxylamin trong hn hp

    NaOH, MeOH iu kin 0oC n nhit phng vi hiu sut kh cao (s 1.10).

    S 1.10. Tng hp mt s dn cht amid ngc ca SAHA [6]

    Ty thuc vo bn cht ca cht tham gia phn ng, iu kin phn ng v

    dung mi c th thay i cho ph hp. Trong nghin cu tng hp cc acid

    hydroxamic c cu ni cha vng triazol, Chen v cng s [17] tin hnh tng hp

    acid hydroxamic t dn cht methyl ester vi dung dch hydroxylamin trong hn hp

    KCN:THF (1:1) nhit phng, hiu sut phn ng cng rt cao (>80%).

    1.4.2.2. Tng hp acid hydroxamic t acid carboxylic

    Trong mt s trng hp, phn ng trc tip gia dn cht methyl ester v

    hydroxylamin khng th xy ra. Khi , nhiu nhm nghin cu la chn phng

    php s dng tc nhn hot ha acid carboxylic ng thi s dng hydroxylamin c

    nhm bo v -OH tng kh nng phn ng vo nhm -NH2.

    tng hp cc dn cht acid 5-pyridin-2-yl-thiophen-2-hydroxamic, Price v

    cng s [67] s dng tc nhn hot ha HATU to ester hot ha ngay trong

    phn ng, ng thi s dng hydroxylamin tetrahydropyran. Sau , nhm bo v -

    OH c tch bi acid p-TSA hoc HCl 4M trong dioxan. Phn ng tri qua 2 bc

    do vy hiu sut tng ch t c khong 40 50%.

  • 46

    S 1.11. Tng hp acid biaryl hydroxamic [67]

    Song song, nhiu tc nhn hot ha khc cng c cc nhm nghin cu s

    dng trong tng hp acid hydroxamic. Isobutyl cloroformat c Kozikowski v cng

    s [51] dng trong phn ng tng hp cc acid phenylthiazol hydroxamic. Phn ng

    tin hnh 0oC, to anhydrid hn tp ngay trong phn ng. y l tc nhn acyl ha

    mnh nn hydroxylamin phn ng trc tip, khng cn s dng loi c nhm bo v -

    OH. Tuy nhin, hiu sut phn ng khng cao, khong 26-30% (s 1.12).

    S 1.12. Tng hp cc acid phenylthiazol hydroxamic [51]

    Nh vy, c hai phng php ch yu tng hp acid hydroxamic vi cc tc

    nhn hot ha khc nhau. Ty vo nguyn liu ban u v sn phm, cc nh ha hc

    c th la chn phng php v cc tc nhn hot ha ph hp.

  • 47

    Chng 2

    NGUYN LIU, THIT B, NI DUNG

    V PHNG PHP NGHIN CU

    2.1. NGUYN LIU

    Cc ha cht, dung mi dng trong thc nghim c trnh by trong bng di

    y:

    TT Nguyn liu Xut x TT Nguyn liu Xut x

    1 2-Aminobenzothiazol Aldrich 21 Acid adipic monomethyl ester Aldrich

    2 2-Amino-6-methylbenzothiazol Aldrich 22 Acid suberic monomethyl ester Aldrich

    3 2-Amino-6-methoxybenzothiazol Aldrich 23 Anhydrid succinic Trung quc

    4 2-Amino-6-ethoxybenzothiazol Aldrich 24 Anhydrid glutaric Merck

    5 2-Amino-6-methylsulfonylbenzothiazol

    Aldrich 25 N,N-dicyclohexylcarbodiimid Merck

    6 2-Amino-6-nitrobenzothiazol Aldrich 26 Hydroxylamin HCl Merck

    7 2-Amino-6-clorobenzothiazol Aldrich 27 Dimethylformamid Merck

    8 2-Amino-6-trifluoromethylbenzothiazol

    Aldrich 28 Triethylamin Merck

    9 2-Aminothiazol Merck 29 Isobutylcloroformat Merck

    10 Anilin Merck 30 Tetrahydrofuran Merck

    11 2-Cloroanilin Merck 31 Aceton Trung quc

    12 3-Cloroanilin Merck 32 Ethanol Trung quc

    13 4-Cloroanilin Merck 33 n-Hexan Trung quc

    14 4-Fluoroanilin Merck 34 Methanol Trung quc

    15 4-Methoxyanilin Merck 35 Acid hydrocloric c Trung quc

    16 4-Nitroanilin Merck 36 Natri hydroxid Trung quc

    17 4-Cyanoanilin Merck 37 Pyridin Merck

    18 -Alanin methyl ester.HCl Aldrich 38 O-tetrahydropyranyl hydroxylamin Aldrich

    19 Glycin methyl ester.HCl Aldrich 39 Acid para-toluensulfonic Aldrich

    20 Carbonyldiimidazol Merck 40 Liti hydroxyd Trung quc

  • 48

    2.2. THIT B

    - Cc dng c thy tinh: bnh cu y trn dung tch 50 - 100 ml, bnh chit, sinh hn

    hi lu, ng nghim, ng ong, pipet, cc c m cc loi.

    - Bnh sc k Camag, n t ngoi Camag bc sng 254 nm v 366 nm, bn mng

    silicagel F254 (Merck).

    - Cn phn tch, cn k thut Shimazu.

    - T lnh, t sy Memmert.

    - My ct quay Buchi R-210, my khuy t gia nhit IKA-RTC, my o nhit nng

    chy nhit in Electrothermal digital.

    - My o ph hng ngoi:

    - Perkin Elmer, phng th nghim trung tm - Trng i hc Dc H N